Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,27300254,half-life,"Erythrocyte sequestration (half-life = 50.2 ± 18.5 h, mean ± SD, n = 6), resulted in the acetazolamide microdose exhibiting a substantially longer plasma half-life (24.5 ± 5.6 hours, n = 10) than previously reported for therapeutic doses (3-6 hours).",A Pharmacokinetic Study Examining Acetazolamide as a Novel Adherence Marker for Clinical Trials. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27300254/),h,50.2,8778,DB00497,Oxycodone
,27300254,plasma half-life,"Erythrocyte sequestration (half-life = 50.2 ± 18.5 h, mean ± SD, n = 6), resulted in the acetazolamide microdose exhibiting a substantially longer plasma half-life (24.5 ± 5.6 hours, n = 10) than previously reported for therapeutic doses (3-6 hours).",A Pharmacokinetic Study Examining Acetazolamide as a Novel Adherence Marker for Clinical Trials. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27300254/),h,24.5,8779,DB00497,Oxycodone
,27300254,plasma half-life,"Erythrocyte sequestration (half-life = 50.2 ± 18.5 h, mean ± SD, n = 6), resulted in the acetazolamide microdose exhibiting a substantially longer plasma half-life (24.5 ± 5.6 hours, n = 10) than previously reported for therapeutic doses (3-6 hours).",A Pharmacokinetic Study Examining Acetazolamide as a Novel Adherence Marker for Clinical Trials. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27300254/),h,3-6,8780,DB00497,Oxycodone
,27300254,half-life,"After cessation of dosing, the rate of urinary elimination decreased significantly (F3,23 = 247: P < 0.05, n = 6) in a predictable manner with low intersubject variability and a half-life of 16.1 ± 3.8 h (n = 10).",A Pharmacokinetic Study Examining Acetazolamide as a Novel Adherence Marker for Clinical Trials. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27300254/),h,16.1,8781,DB00497,Oxycodone
,22973910,V(d),"Population pharmacokinetics of oxycodone at the end point were as follows: CL(L/h) = 10.7 × [1 + (2 - Child-Pugh Classification)] (Class: A = 0, B = 1, C = 2); V(d) (L) = 193; k(a) (h(-1)) = 0.336; T(lag) (h) = 0.859; F (%) = 63.9.",Population pharmacokinetics of oxycodone in patients with cancer-related pain. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22973910/),l,193,17347,DB00497,Oxycodone
,22973910,k(a),"Population pharmacokinetics of oxycodone at the end point were as follows: CL(L/h) = 10.7 × [1 + (2 - Child-Pugh Classification)] (Class: A = 0, B = 1, C = 2); V(d) (L) = 193; k(a) (h(-1)) = 0.336; T(lag) (h) = 0.859; F (%) = 63.9.",Population pharmacokinetics of oxycodone in patients with cancer-related pain. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22973910/),1/[h],0.336,17348,DB00497,Oxycodone
,22973910,T(lag),"Population pharmacokinetics of oxycodone at the end point were as follows: CL(L/h) = 10.7 × [1 + (2 - Child-Pugh Classification)] (Class: A = 0, B = 1, C = 2); V(d) (L) = 193; k(a) (h(-1)) = 0.336; T(lag) (h) = 0.859; F (%) = 63.9.",Population pharmacokinetics of oxycodone in patients with cancer-related pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22973910/),h,0.859,17349,DB00497,Oxycodone
,27633773,E max,Median Drug Liking VAS E max was significantly lower after treatment with manipulated morphine-ADER-IMT (67) compared with manipulated morphine ER (74; P = 0.007).,"Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) versus Extended-Release Morphine Administered Orally in Nondependent Recreational Opioid Users. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27633773/),,67,25062,DB00497,Oxycodone
,27633773,E max,Median Drug Liking VAS E max was significantly lower after treatment with manipulated morphine-ADER-IMT (67) compared with manipulated morphine ER (74; P = 0.007).,"Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) versus Extended-Release Morphine Administered Orally in Nondependent Recreational Opioid Users. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27633773/),,74,25063,DB00497,Oxycodone
,25359452,clearance (CL),"The estimated geometric mean clearance (CL) of oxycodone was 24.3 L per hour after constant intravenous infusion and 29.5 L per hour after constant subcutaneous infusion, respectively.",Pharmacokinetics of oxycodone after intravenous and subcutaneous administration in Japanese patients with cancer pain. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25359452/),[l] / [h],24.3,29288,DB00497,Oxycodone
,25359452,clearance (CL),"The estimated geometric mean clearance (CL) of oxycodone was 24.3 L per hour after constant intravenous infusion and 29.5 L per hour after constant subcutaneous infusion, respectively.",Pharmacokinetics of oxycodone after intravenous and subcutaneous administration in Japanese patients with cancer pain. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25359452/),[l] / [h],29.5,29289,DB00497,Oxycodone
,22541841,absolute bioavailability,"The mean absolute bioavailability of naloxone from the orally administered PR tablets was very low, ranging from 0.9% for the 5 mg dose to 2% for the 40, 80 and 120 mg doses, based on AUC(t) values.",Low absolute bioavailability of oral naloxone in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541841/),%,0.9,30364,DB00497,Oxycodone
,22541841,absolute bioavailability,"The mean absolute bioavailability of naloxone from the orally administered PR tablets was very low, ranging from 0.9% for the 5 mg dose to 2% for the 40, 80 and 120 mg doses, based on AUC(t) values.",Low absolute bioavailability of oral naloxone in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541841/),%,2,30365,DB00497,Oxycodone
,22541841,absolute bioavailability,"Where AUC(inf) values were calculated, these confirmed the results based on AUC(t) values (mean absolute bioavailability ranging from 1.9% to 2.2% for the 20 mg to 120 mg oral doses).",Low absolute bioavailability of oral naloxone in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541841/),%,1.9,30366,DB00497,Oxycodone
,22541841,absolute bioavailability,"Where AUC(inf) values were calculated, these confirmed the results based on AUC(t) values (mean absolute bioavailability ranging from 1.9% to 2.2% for the 20 mg to 120 mg oral doses).",Low absolute bioavailability of oral naloxone in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541841/),%,2.2,30367,DB00497,Oxycodone
,22541841,absolute bioavailability,"The absolute bioavailability of naloxone was higher following rectal administration compared with oral administration, but was still low at 15%.",Low absolute bioavailability of oral naloxone in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541841/),%,15,30368,DB00497,Oxycodone
≤,22541841,oral absolute bioavailability,The mean oral absolute bioavailability of naloxone in this study was ≤ 2% at doses ranging from 5 mg to 120 mg.,Low absolute bioavailability of oral naloxone in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541841/),%,2,30369,DB00497,Oxycodone
,26218586,clearance (CL/F),"The average PK estimates for OC were 75 L/hour for clearance (CL/F), 756 L for volume of distribution (V/F), and 0.581 per hour for absorption rate constant (Ka ).",Pooled Post Hoc Analysis of Population Pharmacokinetics of Oxycodone and Acetaminophen Following Multiple Oral Doses of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26218586/),[l] / [h],75,38897,DB00497,Oxycodone
,26218586,volume of distribution (V/F),"The average PK estimates for OC were 75 L/hour for clearance (CL/F), 756 L for volume of distribution (V/F), and 0.581 per hour for absorption rate constant (Ka ).",Pooled Post Hoc Analysis of Population Pharmacokinetics of Oxycodone and Acetaminophen Following Multiple Oral Doses of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26218586/),l,756,38898,DB00497,Oxycodone
,26218586,absorption rate constant (Ka ),"The average PK estimates for OC were 75 L/hour for clearance (CL/F), 756 L for volume of distribution (V/F), and 0.581 per hour for absorption rate constant (Ka ).",Pooled Post Hoc Analysis of Population Pharmacokinetics of Oxycodone and Acetaminophen Following Multiple Oral Doses of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26218586/),1/[h],0.581,38899,DB00497,Oxycodone
,26218586,CL/F,Average estimates for APAP were 25 L/hour for CL/F and 119 L for V/F.,Pooled Post Hoc Analysis of Population Pharmacokinetics of Oxycodone and Acetaminophen Following Multiple Oral Doses of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26218586/),[l] / [h],25,38900,DB00497,Oxycodone
,26218586,V/F,Average estimates for APAP were 25 L/hour for CL/F and 119 L for V/F.,Pooled Post Hoc Analysis of Population Pharmacokinetics of Oxycodone and Acetaminophen Following Multiple Oral Doses of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26218586/),l,119,38901,DB00497,Oxycodone
,26218586,CL/F,Sex was identified as a statistically significant source of variability in CL/F with predicted values for APAP of 25 L/hour in men and 21 L/hour in women.,Pooled Post Hoc Analysis of Population Pharmacokinetics of Oxycodone and Acetaminophen Following Multiple Oral Doses of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26218586/),[l] / [h],25,38902,DB00497,Oxycodone
,26218586,CL/F,Sex was identified as a statistically significant source of variability in CL/F with predicted values for APAP of 25 L/hour in men and 21 L/hour in women.,Pooled Post Hoc Analysis of Population Pharmacokinetics of Oxycodone and Acetaminophen Following Multiple Oral Doses of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26218586/),[l] / [h],21,38903,DB00497,Oxycodone
,26218586,V/F,"Body weight affected variability in V/F, with a predicted value of 193 L in men and 174 L in women for a 72-kg participant at steady state.",Pooled Post Hoc Analysis of Population Pharmacokinetics of Oxycodone and Acetaminophen Following Multiple Oral Doses of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26218586/),l,193,38904,DB00497,Oxycodone
,26218586,V/F,"Body weight affected variability in V/F, with a predicted value of 193 L in men and 174 L in women for a 72-kg participant at steady state.",Pooled Post Hoc Analysis of Population Pharmacokinetics of Oxycodone and Acetaminophen Following Multiple Oral Doses of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26218586/),l,174,38905,DB00497,Oxycodone
,1389934,Cmax,"3. No differences were found between treatments in mean Cmax and AUC values of oxycodone which varied from 34 to 38 ng ml-1 and from 208 to 245 ng ml-1 h, respectively.",The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1389934/),[ng] / [ml],34 to 38,38910,DB00497,Oxycodone
,1389934,AUC,"3. No differences were found between treatments in mean Cmax and AUC values of oxycodone which varied from 34 to 38 ng ml-1 and from 208 to 245 ng ml-1 h, respectively.",The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1389934/),[h·ng] / [ml],208 to 245,38911,DB00497,Oxycodone
,1389934,tmax,The median tmax of oxycodone was 1 h in all groups.,The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1389934/),h,1,38912,DB00497,Oxycodone
,1389934,bioavailability,The bioavailability of oral relative to i.m. oxycodone was 60%.,The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1389934/),%,60,38913,DB00497,Oxycodone
,1389934,renal clearance,The mean renal clearance of oxycodone was 0.07-0.08 l min-1.,The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1389934/),[l] / [min],0.07-0.08,38914,DB00497,Oxycodone
,24633923,"Cp,u","Oxycodone and diphenhydramine have CISF :Cp,u of 3.0 and 5.5, respectively, while CE-157119 has an unbound brain compound concentration (Cb,u ):Cp,u of 3.90; Cb,u is a high-confidence CISF surrogate.",Diphenhydramine has similar interspecies net active influx at the blood-brain barrier. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24633923/),,3.0,42982,DB00497,Oxycodone
,24633923,"Cp,u","Oxycodone and diphenhydramine have CISF :Cp,u of 3.0 and 5.5, respectively, while CE-157119 has an unbound brain compound concentration (Cb,u ):Cp,u of 3.90; Cb,u is a high-confidence CISF surrogate.",Diphenhydramine has similar interspecies net active influx at the blood-brain barrier. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24633923/),,5.5,42983,DB00497,Oxycodone
,24633923,"Cp,u","Oxycodone and diphenhydramine have CISF :Cp,u of 3.0 and 5.5, respectively, while CE-157119 has an unbound brain compound concentration (Cb,u ):Cp,u of 3.90; Cb,u is a high-confidence CISF surrogate.",Diphenhydramine has similar interspecies net active influx at the blood-brain barrier. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24633923/),,3.90,42984,DB00497,Oxycodone
,24633923,"Cb,u :Cp,u","However, only CE-157119 has published dog and nonhuman primate (nhp) neuropharmacokinetics, which show similar Cb,u :Cp,u (4.61 and 2.04, respectively) as rats.",Diphenhydramine has similar interspecies net active influx at the blood-brain barrier. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24633923/),,4.61,42985,DB00497,Oxycodone
,24633923,"Cb,u :Cp,u","However, only CE-157119 has published dog and nonhuman primate (nhp) neuropharmacokinetics, which show similar Cb,u :Cp,u (4.61 and 2.04, respectively) as rats.",Diphenhydramine has similar interspecies net active influx at the blood-brain barrier. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24633923/),,2.04,42986,DB00497,Oxycodone
,24633923,"Cb,u :Cp,u","The single-dose-derived rat Cb,u :Cp,u (3.90) was consistent with prior steady-state-derived CISF :Cp,u and similar to those in dogs (4.88) and nhp (4.51-5.00).",Diphenhydramine has similar interspecies net active influx at the blood-brain barrier. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24633923/),,3.90,42987,DB00497,Oxycodone
,24633923,"Cb,u :Cp,u","The single-dose-derived rat Cb,u :Cp,u (3.90) was consistent with prior steady-state-derived CISF :Cp,u and similar to those in dogs (4.88) and nhp (4.51-5.00).",Diphenhydramine has similar interspecies net active influx at the blood-brain barrier. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24633923/),,4.88,42988,DB00497,Oxycodone
,25392115,Cmax,"The main pharmacokinetic parameters for oxycodone in men (n = 14) and women (n = 10) were as follows: Cmax, 14.40 (3.76) and 11.54 (6.98) ng/ml (p = 0.2066); AUC0-∞, 157.87 (56.89) and 106.44 (61.31) ng´h/ml (p = 0.0460); tmax, 2.18 (0.58) and 2.15 (0.58) h (p = 0.8008), respectively.",The pharmacokinetics of oral oxycodone in patients after total gastric resection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25392115/),[ng] / [ml],14.40,52417,DB00497,Oxycodone
,25392115,Cmax,"The main pharmacokinetic parameters for oxycodone in men (n = 14) and women (n = 10) were as follows: Cmax, 14.40 (3.76) and 11.54 (6.98) ng/ml (p = 0.2066); AUC0-∞, 157.87 (56.89) and 106.44 (61.31) ng´h/ml (p = 0.0460); tmax, 2.18 (0.58) and 2.15 (0.58) h (p = 0.8008), respectively.",The pharmacokinetics of oral oxycodone in patients after total gastric resection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25392115/),[ng] / [ml],11.54,52418,DB00497,Oxycodone
,25392115,AUC0-∞,"The main pharmacokinetic parameters for oxycodone in men (n = 14) and women (n = 10) were as follows: Cmax, 14.40 (3.76) and 11.54 (6.98) ng/ml (p = 0.2066); AUC0-∞, 157.87 (56.89) and 106.44 (61.31) ng´h/ml (p = 0.0460); tmax, 2.18 (0.58) and 2.15 (0.58) h (p = 0.8008), respectively.",The pharmacokinetics of oral oxycodone in patients after total gastric resection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25392115/),[ng´h] / [ml],157.87,52419,DB00497,Oxycodone
,25392115,AUC0-∞,"The main pharmacokinetic parameters for oxycodone in men (n = 14) and women (n = 10) were as follows: Cmax, 14.40 (3.76) and 11.54 (6.98) ng/ml (p = 0.2066); AUC0-∞, 157.87 (56.89) and 106.44 (61.31) ng´h/ml (p = 0.0460); tmax, 2.18 (0.58) and 2.15 (0.58) h (p = 0.8008), respectively.",The pharmacokinetics of oral oxycodone in patients after total gastric resection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25392115/),[ng´h] / [ml],106.44,52420,DB00497,Oxycodone
,25392115,tmax,"The main pharmacokinetic parameters for oxycodone in men (n = 14) and women (n = 10) were as follows: Cmax, 14.40 (3.76) and 11.54 (6.98) ng/ml (p = 0.2066); AUC0-∞, 157.87 (56.89) and 106.44 (61.31) ng´h/ml (p = 0.0460); tmax, 2.18 (0.58) and 2.15 (0.58) h (p = 0.8008), respectively.",The pharmacokinetics of oral oxycodone in patients after total gastric resection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25392115/),h,2.18,52421,DB00497,Oxycodone
,25392115,tmax,"The main pharmacokinetic parameters for oxycodone in men (n = 14) and women (n = 10) were as follows: Cmax, 14.40 (3.76) and 11.54 (6.98) ng/ml (p = 0.2066); AUC0-∞, 157.87 (56.89) and 106.44 (61.31) ng´h/ml (p = 0.0460); tmax, 2.18 (0.58) and 2.15 (0.58) h (p = 0.8008), respectively.",The pharmacokinetics of oral oxycodone in patients after total gastric resection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25392115/),h,2.15,52422,DB00497,Oxycodone
,1424423,elimination half-life,"The mean +/- SD elimination half-life after single-dose administration of intravenous (4.6 mg to 9.1 mg) and oral (9.1 mg) oxycodone was 3.01 +/- 1.37 hours and 3.51 +/- 1.43 hours, respectively.",Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424423/),h,3.01,58931,DB00497,Oxycodone
,1424423,elimination half-life,"The mean +/- SD elimination half-life after single-dose administration of intravenous (4.6 mg to 9.1 mg) and oral (9.1 mg) oxycodone was 3.01 +/- 1.37 hours and 3.51 +/- 1.43 hours, respectively.",Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424423/),h,3.51,58932,DB00497,Oxycodone
,1424423,volume of distribution,"After intravenous administration, the mean +/- SD volume of distribution was 211.9 +/- 186.6 L, and the mean +/- SD total plasma clearance was 48.6 +/- 26.5 L/hr.",Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424423/),l,211.9,58933,DB00497,Oxycodone
,1424423,total plasma clearance,"After intravenous administration, the mean +/- SD volume of distribution was 211.9 +/- 186.6 L, and the mean +/- SD total plasma clearance was 48.6 +/- 26.5 L/hr.",Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424423/),[l] / [h],48.6,58934,DB00497,Oxycodone
,1424423,absolute oral bioavailability,"The mean absolute oral bioavailability of oxycodone was 87%, and the mean +/- SD volume of distribution after oral administration was 249.1 +/- 204.3 L.",Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424423/),%,87,58935,DB00497,Oxycodone
,1424423,volume of distribution,"The mean absolute oral bioavailability of oxycodone was 87%, and the mean +/- SD volume of distribution after oral administration was 249.1 +/- 204.3 L.",Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424423/),l,249.1,58936,DB00497,Oxycodone
,1424423,steady-state concentration,"When administered orally as 10 mg oxycodone hydrochloride every 4 hours, there was no accumulation of oxycodone at steady state and the mean +/- SD steady-state concentration was 34.6 +/- 10.3 micrograms/L.",Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424423/),[μg] / [l],34.6,58937,DB00497,Oxycodone
,26655109,flow rate,"The chromatographic separation was achieved using gradient elution with a mobile phase consisting of ethanol and 10mM ammonium acetate on a Synergi MAX-RP analytical column (150×2mm, 4μm) protected by a security guard cartridge (C12 4×2mm) at a flow rate of 300μL/min.",Development of a sensitive method for the determination of oxycodone and its major metabolites noroxycodone and oxymorphone in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26655109/),[μl] / [min],300,60351,DB00497,Oxycodone
,26655109,limit of detection,The limit of detection was 30pg/mL for all analytes.,Development of a sensitive method for the determination of oxycodone and its major metabolites noroxycodone and oxymorphone in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26655109/),[pg] / [ml],30,60352,DB00497,Oxycodone
,29772054,clearance,"After 0.1 mg·kg-1 oxycodone intravenously, the median clearance was 5.2 L·h-1 ·kg-1 (range 4.6-6.2), but the volume of distribution varied between 1.5 and 4.7 L·kg-1 .",Oxycodone pharmacokinetics and fetal exposure after intravenous or epidural administration to the ewe. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29772054/),[l] / [h·kg],5.2,69115,DB00497,Oxycodone
,29772054,volume of distribution,"After 0.1 mg·kg-1 oxycodone intravenously, the median clearance was 5.2 L·h-1 ·kg-1 (range 4.6-6.2), but the volume of distribution varied between 1.5 and 4.7 L·kg-1 .",Oxycodone pharmacokinetics and fetal exposure after intravenous or epidural administration to the ewe. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29772054/),[l] / [kg],1.5 and 4.7,69116,DB00497,Oxycodone
,29772054,area under the curve,The area under the curve was 17 h·ng·mL-1 (range 14-19) and the plasma concentration at 2 minutes 60 ng·mL-1 (range 50-74).,Oxycodone pharmacokinetics and fetal exposure after intravenous or epidural administration to the ewe. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29772054/),[h·ng] / [ml],17,69117,DB00497,Oxycodone
,29772054,plasma concentration at 2 minutes,The area under the curve was 17 h·ng·mL-1 (range 14-19) and the plasma concentration at 2 minutes 60 ng·mL-1 (range 50-74).,Oxycodone pharmacokinetics and fetal exposure after intravenous or epidural administration to the ewe. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29772054/),[ng] / [ml],60,69118,DB00497,Oxycodone
,29772054,fetal-to-maternal ratios,Accumulation of oxymorphone in the fetus occurred; fetal-to-maternal ratios were 1.3-3.5 (median 2.1) in the i.v.-group and 0.9-3.0 (1.3) in the Epidural-group.,Oxycodone pharmacokinetics and fetal exposure after intravenous or epidural administration to the ewe. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29772054/),,1.3-3.5,69119,DB00497,Oxycodone
,29772054,fetal-to-maternal ratios,Accumulation of oxymorphone in the fetus occurred; fetal-to-maternal ratios were 1.3-3.5 (median 2.1) in the i.v.-group and 0.9-3.0 (1.3) in the Epidural-group.,Oxycodone pharmacokinetics and fetal exposure after intravenous or epidural administration to the ewe. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29772054/),,2.1,69120,DB00497,Oxycodone
,25724154,time to maximum concentration,Median time to maximum concentration was 12 h postdose when ALO-02 was administered with water or 20 % ethanol and decreased to 8 h postdose with 40 % ethanol.,Effects of ethanol on the pharmacokinetics of extended-release oxycodone with sequestered naltrexone (ALO-02). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25724154/),h,12,72602,DB00497,Oxycodone
,25724154,time to maximum concentration,Median time to maximum concentration was 12 h postdose when ALO-02 was administered with water or 20 % ethanol and decreased to 8 h postdose with 40 % ethanol.,Effects of ethanol on the pharmacokinetics of extended-release oxycodone with sequestered naltrexone (ALO-02). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25724154/),h,8,72603,DB00497,Oxycodone
,15920700,flow rate,"The analytes were separated using a mobile phase, consisting of acetonitrile and phosphate buffer (8:92, v/v) at a flow rate of 1 mL/min, and UV detection at 205 nm.","Simultaneous determination of oxycodone and its major metabolite, noroxycodone, in human plasma by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15920700/),[ml] / [min],1,80383,DB00497,Oxycodone
,15920700,retention times,"The retention times for oxycodone, noroxycodone and codein (internal standard) were 14.7, 13.8 and 10.2 min, respectively.","Simultaneous determination of oxycodone and its major metabolite, noroxycodone, in human plasma by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15920700/),min,14.7,80384,DB00497,Oxycodone
,15920700,retention times,"The retention times for oxycodone, noroxycodone and codein (internal standard) were 14.7, 13.8 and 10.2 min, respectively.","Simultaneous determination of oxycodone and its major metabolite, noroxycodone, in human plasma by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15920700/),min,13.8,80385,DB00497,Oxycodone
,15920700,retention times,"The retention times for oxycodone, noroxycodone and codein (internal standard) were 14.7, 13.8 and 10.2 min, respectively.","Simultaneous determination of oxycodone and its major metabolite, noroxycodone, in human plasma by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15920700/),min,10.2,80386,DB00497,Oxycodone
,16037150,arterial Pco(2),The median arterial Pco(2) level was 41 mm Hg and the interquartile range was 39-46 mm Hg.,"Preoperative ""fentanyl challenge"" as a tool to estimate postoperative opioid dosing in chronic opioid-consuming patients. ",Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16037150/),hg·mm,41,80675,DB00497,Oxycodone
,9209248,elimination half-life,"THe median elimination half-life of oxycodone was 13.9 hours (range, 4.6 to 24.4 hours) in patients with cirrhosis before transplantation and 3.4 hours (range, 2.6 to 5.1 hours) after transplantation (p < 0.05).",Pharmacokinetics and ventilatory effects of oxycodone before and after liver transplantation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209248/),h,13.9,86627,DB00497,Oxycodone
,9209248,elimination half-life,"THe median elimination half-life of oxycodone was 13.9 hours (range, 4.6 to 24.4 hours) in patients with cirrhosis before transplantation and 3.4 hours (range, 2.6 to 5.1 hours) after transplantation (p < 0.05).",Pharmacokinetics and ventilatory effects of oxycodone before and after liver transplantation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209248/),h,3.4,86628,DB00497,Oxycodone
,9209248,clearance,"Correspondingly, oxycodone clearance increased from 0.26 L/min (range, 0.15 to 0.73 L/min) before transplantation to 1.13 L/min (range, 0.71 to 3.98 L/min) after transplantation (p < 0.05).",Pharmacokinetics and ventilatory effects of oxycodone before and after liver transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209248/),[l] / [min],0.26,86629,DB00497,Oxycodone
,9209248,clearance,"Correspondingly, oxycodone clearance increased from 0.26 L/min (range, 0.15 to 0.73 L/min) before transplantation to 1.13 L/min (range, 0.71 to 3.98 L/min) after transplantation (p < 0.05).",Pharmacokinetics and ventilatory effects of oxycodone before and after liver transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209248/),[l] / [min],1.13,86630,DB00497,Oxycodone
,17973932,clearance,"3. The mean (+/-SEM) clearance of intravenous oxycodone was significantly higher in male than female SD rats (4.9 +/- 0.3 vs 3.1 +/- 0.3 L/h per kg, respectively; P < 0.01).","Sex differences in the pharmacokinetics, oxidative metabolism and oral bioavailability of oxycodone in the Sprague-Dawley rat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17973932/),[l] / [h·kg],4.9,90976,DB00497,Oxycodone
,17973932,clearance,"3. The mean (+/-SEM) clearance of intravenous oxycodone was significantly higher in male than female SD rats (4.9 +/- 0.3 vs 3.1 +/- 0.3 L/h per kg, respectively; P < 0.01).","Sex differences in the pharmacokinetics, oxidative metabolism and oral bioavailability of oxycodone in the Sprague-Dawley rat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17973932/),[l] / [h·kg],3.1,90977,DB00497,Oxycodone
,17973932,oral bioavailability,"4. The oral bioavailability of oxycodone was low (at 1.2 and 5.0%, respectively) in male and female SD rats, a finding consistent with high first-pass metabolism.","Sex differences in the pharmacokinetics, oxidative metabolism and oral bioavailability of oxycodone in the Sprague-Dawley rat. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17973932/),%,1.2,90978,DB00497,Oxycodone
,17973932,oral bioavailability,"4. The oral bioavailability of oxycodone was low (at 1.2 and 5.0%, respectively) in male and female SD rats, a finding consistent with high first-pass metabolism.","Sex differences in the pharmacokinetics, oxidative metabolism and oral bioavailability of oxycodone in the Sprague-Dawley rat. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17973932/),%,5.0,90979,DB00497,Oxycodone
,15217304,peak drug concentration,"The peak drug concentration observed was 57-110 (mean 82) microg/L after intravenous administration, 23-54 (34) microg/L after intramuscular administration, 3.9-14 (9.8) microg/L after buccal administration and 1.7-15 (9.2) microg/L after gastric administration.","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),[μg] / [l],57-110,93726,DB00497,Oxycodone
,15217304,peak drug concentration,"The peak drug concentration observed was 57-110 (mean 82) microg/L after intravenous administration, 23-54 (34) microg/L after intramuscular administration, 3.9-14 (9.8) microg/L after buccal administration and 1.7-15 (9.2) microg/L after gastric administration.","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),[μg] / [l],23-54,93727,DB00497,Oxycodone
,15217304,peak drug concentration,"The peak drug concentration observed was 57-110 (mean 82) microg/L after intravenous administration, 23-54 (34) microg/L after intramuscular administration, 3.9-14 (9.8) microg/L after buccal administration and 1.7-15 (9.2) microg/L after gastric administration.","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),[μg] / [l],3.9-14,93728,DB00497,Oxycodone
,15217304,peak drug concentration,"The peak drug concentration observed was 57-110 (mean 82) microg/L after intravenous administration, 23-54 (34) microg/L after intramuscular administration, 3.9-14 (9.8) microg/L after buccal administration and 1.7-15 (9.2) microg/L after gastric administration.","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),[μg] / [l],1.7-15,93729,DB00497,Oxycodone
,15217304,time to peak concentration,"The time to peak concentration was 2-30 (16) minutes in the intramuscular group, 30-480 (221) minutes in the buccal group and 60-360 (193) minutes in the gastric group.","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),min,2-30,93730,DB00497,Oxycodone
,15217304,time to peak concentration,"The time to peak concentration was 2-30 (16) minutes in the intramuscular group, 30-480 (221) minutes in the buccal group and 60-360 (193) minutes in the gastric group.","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),min,30-480,93731,DB00497,Oxycodone
,15217304,time to peak concentration,"The time to peak concentration was 2-30 (16) minutes in the intramuscular group, 30-480 (221) minutes in the buccal group and 60-360 (193) minutes in the gastric group.","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),min,60-360,93732,DB00497,Oxycodone
,15217304,terminal elimination half-lives,"The terminal elimination half-lives were closely similar in the four groups: 124-208 (163) minutes in the intravenous group, 162-227 (150) minutes in the intramuscular group, 73-234 (150) minutes in the buccal group and 80-246 (147) minutes in the gastric group.","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),min,124-208,93733,DB00497,Oxycodone
,15217304,terminal elimination half-lives,"The terminal elimination half-lives were closely similar in the four groups: 124-208 (163) minutes in the intravenous group, 162-227 (150) minutes in the intramuscular group, 73-234 (150) minutes in the buccal group and 80-246 (147) minutes in the gastric group.","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),min,162-227,93734,DB00497,Oxycodone
,15217304,terminal elimination half-lives,"The terminal elimination half-lives were closely similar in the four groups: 124-208 (163) minutes in the intravenous group, 162-227 (150) minutes in the intramuscular group, 73-234 (150) minutes in the buccal group and 80-246 (147) minutes in the gastric group.","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),min,73-234,93735,DB00497,Oxycodone
,15217304,terminal elimination half-lives,"The terminal elimination half-lives were closely similar in the four groups: 124-208 (163) minutes in the intravenous group, 162-227 (150) minutes in the intramuscular group, 73-234 (150) minutes in the buccal group and 80-246 (147) minutes in the gastric group.","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),min,80-246,93736,DB00497,Oxycodone
,15217304,Area under the concentration-time curve (AUC),"Area under the concentration-time curve (AUC) was 5037-8954 (6612) microg x min/L in the intravenous group, 3084-5524 (4473) microg x min/L in the intramuscular group, 1444-5560 (3658) microg x min/L in the buccal group and 692-3843 (2436) microg x min/L in the gastric group.","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),[min·μg] / [l],5037-8954,93737,DB00497,Oxycodone
,15217304,Area under the concentration-time curve (AUC),"Area under the concentration-time curve (AUC) was 5037-8954 (6612) microg x min/L in the intravenous group, 3084-5524 (4473) microg x min/L in the intramuscular group, 1444-5560 (3658) microg x min/L in the buccal group and 692-3843 (2436) microg x min/L in the gastric group.","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),[min·μg] / [l],3084-5524,93738,DB00497,Oxycodone
,15217304,Area under the concentration-time curve (AUC),"Area under the concentration-time curve (AUC) was 5037-8954 (6612) microg x min/L in the intravenous group, 3084-5524 (4473) microg x min/L in the intramuscular group, 1444-5560 (3658) microg x min/L in the buccal group and 692-3843 (2436) microg x min/L in the gastric group.","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),[min·μg] / [l],1444-5560,93739,DB00497,Oxycodone
,15217304,Area under the concentration-time curve (AUC),"Area under the concentration-time curve (AUC) was 5037-8954 (6612) microg x min/L in the intravenous group, 3084-5524 (4473) microg x min/L in the intramuscular group, 1444-5560 (3658) microg x min/L in the buccal group and 692-3843 (2436) microg x min/L in the gastric group.","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),[min·μg] / [l],692-3843,93740,DB00497,Oxycodone
,15217304,bioavailability (AUC/,"The estimated bioavailability (AUC/mean intravenous AUC) of intramuscular oxycodone was 0.47-0.84 (0.68), that of buccal oxycodone 0.22-0.84 (0.55) and that of gastric oxycodone 0.10-0.58 (0.37).","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),,0.47-0.84,93741,DB00497,Oxycodone
,15217304,bioavailability (AUC/,"The estimated bioavailability (AUC/mean intravenous AUC) of intramuscular oxycodone was 0.47-0.84 (0.68), that of buccal oxycodone 0.22-0.84 (0.55) and that of gastric oxycodone 0.10-0.58 (0.37).","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),,0.22-0.84,93742,DB00497,Oxycodone
,15217304,bioavailability (AUC/,"The estimated bioavailability (AUC/mean intravenous AUC) of intramuscular oxycodone was 0.47-0.84 (0.68), that of buccal oxycodone 0.22-0.84 (0.55) and that of gastric oxycodone 0.10-0.58 (0.37).","Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217304/),,0.10-0.58,93743,DB00497,Oxycodone
,8971431,t1/2abs,The absorption profile of the CR tablets was characterized by a rapid absorption component (t1/2abs = 37 min) accounting for 38% of the available dose and a slow absorption phase (t1/2abs = 6.2 h) accounting for 62% of the available dose.,Characterization and validation of a pharmacokinetic model for controlled-release oxycodone. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971431/),min,37,96178,DB00497,Oxycodone
,8971431,t1/2abs,The absorption profile of the CR tablets was characterized by a rapid absorption component (t1/2abs = 37 min) accounting for 38% of the available dose and a slow absorption phase (t1/2abs = 6.2 h) accounting for 62% of the available dose.,Characterization and validation of a pharmacokinetic model for controlled-release oxycodone. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971431/),h,6.2,96179,DB00497,Oxycodone
,8971431,bioavailable,Two 10 mg tablets of oral CR oxycodone hydrochloride were 102.7% bioavailable relative to 20 mg of IR oxycodone hydrochloride oral solution.,Characterization and validation of a pharmacokinetic model for controlled-release oxycodone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971431/),%,102.7,96180,DB00497,Oxycodone
,26032168,plasma Tmax,Quinine displayed a plasma Tmax ∼2 hours and t1/2 ∼10 hours.,Quinine as a potential tracer for medication adherence: A pharmacokinetic and pharmacodynamic assessment of quinine alone and in combination with oxycodone in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26032168/),h,∼2,98635,DB00497,Oxycodone
,26032168,t1/2,Quinine displayed a plasma Tmax ∼2 hours and t1/2 ∼10 hours.,Quinine as a potential tracer for medication adherence: A pharmacokinetic and pharmacodynamic assessment of quinine alone and in combination with oxycodone in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26032168/),h,∼10,98636,DB00497,Oxycodone
,26032168,elimination t1/2,"During washout, quinine urinary concentrations steadily declined (elimination t1/2 ∼16 hours), with a 94% decrease observed 72 hours postdose.",Quinine as a potential tracer for medication adherence: A pharmacokinetic and pharmacodynamic assessment of quinine alone and in combination with oxycodone in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26032168/),h,∼16,98637,DB00497,Oxycodone
<,30248201,clearance,Drugs with low clearance (<1 mL/[kg·min]) are likely to cause an infant exposure level greater than 10% of the weight-adjusted maternal dose even if the milk-to-plasma concentration ratio is 1.,Opioids in Breast Milk: Pharmacokinetic Principles and Clinical Implications. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30248201/),[ml] / [kg·min],1,99196,DB00497,Oxycodone
,30248201,milk-to-plasma concentration ratio,Drugs with low clearance (<1 mL/[kg·min]) are likely to cause an infant exposure level greater than 10% of the weight-adjusted maternal dose even if the milk-to-plasma concentration ratio is 1.,Opioids in Breast Milk: Pharmacokinetic Principles and Clinical Implications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30248201/),,1,99197,DB00497,Oxycodone
,22448718,half-life,"Maternal plasma oxycodone concentration decreased with a median half-life of 2.6 hr (range, 1.8-2.8).",Intravenous oxycodone for pain relief in the first stage of labour--maternal pharmacokinetics and neonatal exposure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22448718/),h,2.6,99803,DB00497,Oxycodone
,17978495,V(d),"The pharmacokinetic parameters were as follows: Oxycodone; V(d)=226.7+/-105.5 l (mean+/-S.D.), CL=37.9+/-25.1 l/h, t(1/2)=4.1+/-1.9 h.",Pharmacokinetics and variation in the clearance of oxycodone and hydrocotarnine in patients with cancer pain. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17978495/),l,226.7,103671,DB00497,Oxycodone
,17978495,CL,"The pharmacokinetic parameters were as follows: Oxycodone; V(d)=226.7+/-105.5 l (mean+/-S.D.), CL=37.9+/-25.1 l/h, t(1/2)=4.1+/-1.9 h.",Pharmacokinetics and variation in the clearance of oxycodone and hydrocotarnine in patients with cancer pain. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17978495/),[l] / [h],37.9,103672,DB00497,Oxycodone
,17978495,t(1/2),"The pharmacokinetic parameters were as follows: Oxycodone; V(d)=226.7+/-105.5 l (mean+/-S.D.), CL=37.9+/-25.1 l/h, t(1/2)=4.1+/-1.9 h.",Pharmacokinetics and variation in the clearance of oxycodone and hydrocotarnine in patients with cancer pain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17978495/),h,4.1,103673,DB00497,Oxycodone
,17978495,V(d),"Hydrocotarnine; V(d)=276.8+/-237.2 l, CL=95.1+/-64.3 l/h, t(1/2)=2.0+/-0.7 h.",Pharmacokinetics and variation in the clearance of oxycodone and hydrocotarnine in patients with cancer pain. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17978495/),l,276.8,103674,DB00497,Oxycodone
,17978495,CL,"Hydrocotarnine; V(d)=276.8+/-237.2 l, CL=95.1+/-64.3 l/h, t(1/2)=2.0+/-0.7 h.",Pharmacokinetics and variation in the clearance of oxycodone and hydrocotarnine in patients with cancer pain. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17978495/),[l] / [h],95.1,103675,DB00497,Oxycodone
,17978495,t(1/2),"Hydrocotarnine; V(d)=276.8+/-237.2 l, CL=95.1+/-64.3 l/h, t(1/2)=2.0+/-0.7 h.",Pharmacokinetics and variation in the clearance of oxycodone and hydrocotarnine in patients with cancer pain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17978495/),h,2.0,103676,DB00497,Oxycodone
,24905321,AUC(0-t) ratio,"The mean AUC(0-t) ratio of noroxycodone to oxycodone ranged from 0.35 to 0.42 over three doses, and those of noroxymorphone, or oxymorphone, to oxycodone were ranging of 0.06-0.08 and 0.007-0.008, respectively.",Pharmacokinetics of oxycodone hydrochloride and three of its metabolites after intravenous administration in Chinese patients with pain. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24905321/),,0.35 to 0.42,120652,DB00497,Oxycodone
,24905321,AUC(0-t) ratio,"The mean AUC(0-t) ratio of noroxycodone to oxycodone ranged from 0.35 to 0.42 over three doses, and those of noroxymorphone, or oxymorphone, to oxycodone were ranging of 0.06-0.08 and 0.007-0.008, respectively.",Pharmacokinetics of oxycodone hydrochloride and three of its metabolites after intravenous administration in Chinese patients with pain. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24905321/),,0.06-0.08,120653,DB00497,Oxycodone
,24905321,AUC(0-t) ratio,"The mean AUC(0-t) ratio of noroxycodone to oxycodone ranged from 0.35 to 0.42 over three doses, and those of noroxymorphone, or oxymorphone, to oxycodone were ranging of 0.06-0.08 and 0.007-0.008, respectively.",Pharmacokinetics of oxycodone hydrochloride and three of its metabolites after intravenous administration in Chinese patients with pain. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24905321/),,0,120654,DB00497,Oxycodone
,9062618,plasma clearance,"After intravenous administration of oxycodone, the plasma clearance of oxycodone was 0.83 +/- 0.33 l/min (mean +/- SD) and the volume of distribution at steady-state 2.02 +/- 1.47 l/kg and the terminal elimination half-life 157 +/- 47 min.",Pharmacokinetic comparison of intravenous and intranasal administration of oxycodone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9062618/),[l] / [min],0.83,121549,DB00497,Oxycodone
,9062618,volume of distribution at steady-state,"After intravenous administration of oxycodone, the plasma clearance of oxycodone was 0.83 +/- 0.33 l/min (mean +/- SD) and the volume of distribution at steady-state 2.02 +/- 1.47 l/kg and the terminal elimination half-life 157 +/- 47 min.",Pharmacokinetic comparison of intravenous and intranasal administration of oxycodone. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9062618/),[l] / [kg],2.02,121550,DB00497,Oxycodone
,9062618,terminal elimination half-life,"After intravenous administration of oxycodone, the plasma clearance of oxycodone was 0.83 +/- 0.33 l/min (mean +/- SD) and the volume of distribution at steady-state 2.02 +/- 1.47 l/kg and the terminal elimination half-life 157 +/- 47 min.",Pharmacokinetic comparison of intravenous and intranasal administration of oxycodone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9062618/),min,157,121551,DB00497,Oxycodone
,9062618,peak plasma concentration,"After intranasal administration, peak plasma concentration of oxycodone was 13 +/- 6 ng/ml and it was reached in the median time of 25 min.",Pharmacokinetic comparison of intravenous and intranasal administration of oxycodone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9062618/),[ng] / [ml],13,121552,DB00497,Oxycodone
,9062618,bioavailability,The intranasal bioavailability of oxycodone was 0.46 +/- 0.34.,Pharmacokinetic comparison of intravenous and intranasal administration of oxycodone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9062618/),,0.46,121553,DB00497,Oxycodone
above,1623695,area under the plasma concentration-time curves,Withdrawal symptoms occurred with plasma naloxone area under the plasma concentration-time curves above 550 ng.,Treatment of opioid-induced constipation with oral naloxone: a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1623695/),ng,550,121859,DB00497,Oxycodone
,32939317,tmax,"On POD1 oxycodone absorption was markedly delayed in five of six patients after CECC and in all six patients after OPCAB surgery; median of tmax after CECC 630 [range 270-1420] minutes and after OPCAB 1020 [720-1410] minutes, compared to median of 120-315 min preoperatively and on POD2-POD4.",Bioavailability of oxycodone by mouth in coronary artery bypass surgery patients - a randomized trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32939317/),min,630,122873,DB00497,Oxycodone
,32939317,tmax,"On POD1 oxycodone absorption was markedly delayed in five of six patients after CECC and in all six patients after OPCAB surgery; median of tmax after CECC 630 [range 270-1420] minutes and after OPCAB 1020 [720-1410] minutes, compared to median of 120-315 min preoperatively and on POD2-POD4.",Bioavailability of oxycodone by mouth in coronary artery bypass surgery patients - a randomized trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32939317/),min,1020,122874,DB00497,Oxycodone
,32939317,tmax,"On POD1 oxycodone absorption was markedly delayed in five of six patients after CECC and in all six patients after OPCAB surgery; median of tmax after CECC 630 [range 270-1420] minutes and after OPCAB 1020 [720-1410] minutes, compared to median of 120-315 min preoperatively and on POD2-POD4.",Bioavailability of oxycodone by mouth in coronary artery bypass surgery patients - a randomized trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32939317/),min,120-315,122875,DB00497,Oxycodone
,30713247,milk/plasma concentration ratio,"5) In breastfeeding women, the median milk/plasma concentration ratio of amlodipine was 0.85.",Optimization of Individual Pharmacotherapy Based on Multiple Evaluations of Patient Data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30713247/),,0.85,123684,DB00497,Oxycodone
,17876144,CL/F,"In the result, pharmacokinetic parameters calculated at CL/F were: 45.6+/-22.0 L/hr (Mean+/-SD), Vd/F: 473.0+/-19 6.7 L, t(1/2): 7.2+/- 6.2 hr, kel: 0.103+/-0.034, kal: 1.082+/-0.604, Lag time: 0.9 9+/-0.40 hr.",[Pharmacokinetics of controlled-release oxycodone in patients with cancer pain]. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17876144/),[l] / [h],45.6,126541,DB00497,Oxycodone
,17876144,Vd/F,"In the result, pharmacokinetic parameters calculated at CL/F were: 45.6+/-22.0 L/hr (Mean+/-SD), Vd/F: 473.0+/-19 6.7 L, t(1/2): 7.2+/- 6.2 hr, kel: 0.103+/-0.034, kal: 1.082+/-0.604, Lag time: 0.9 9+/-0.40 hr.",[Pharmacokinetics of controlled-release oxycodone in patients with cancer pain]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17876144/),l,473.0,126542,DB00497,Oxycodone
,17876144,t(1/2),"In the result, pharmacokinetic parameters calculated at CL/F were: 45.6+/-22.0 L/hr (Mean+/-SD), Vd/F: 473.0+/-19 6.7 L, t(1/2): 7.2+/- 6.2 hr, kel: 0.103+/-0.034, kal: 1.082+/-0.604, Lag time: 0.9 9+/-0.40 hr.",[Pharmacokinetics of controlled-release oxycodone in patients with cancer pain]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17876144/),h,7.2,126543,DB00497,Oxycodone
,17876144,kel,"In the result, pharmacokinetic parameters calculated at CL/F were: 45.6+/-22.0 L/hr (Mean+/-SD), Vd/F: 473.0+/-19 6.7 L, t(1/2): 7.2+/- 6.2 hr, kel: 0.103+/-0.034, kal: 1.082+/-0.604, Lag time: 0.9 9+/-0.40 hr.",[Pharmacokinetics of controlled-release oxycodone in patients with cancer pain]. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17876144/),,0.103,126544,DB00497,Oxycodone
,17876144,kal,"In the result, pharmacokinetic parameters calculated at CL/F were: 45.6+/-22.0 L/hr (Mean+/-SD), Vd/F: 473.0+/-19 6.7 L, t(1/2): 7.2+/- 6.2 hr, kel: 0.103+/-0.034, kal: 1.082+/-0.604, Lag time: 0.9 9+/-0.40 hr.",[Pharmacokinetics of controlled-release oxycodone in patients with cancer pain]. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17876144/),,1.082,126545,DB00497,Oxycodone
,17876144,Lag time,"In the result, pharmacokinetic parameters calculated at CL/F were: 45.6+/-22.0 L/hr (Mean+/-SD), Vd/F: 473.0+/-19 6.7 L, t(1/2): 7.2+/- 6.2 hr, kel: 0.103+/-0.034, kal: 1.082+/-0.604, Lag time: 0.9 9+/-0.40 hr.",[Pharmacokinetics of controlled-release oxycodone in patients with cancer pain]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17876144/),h,0.9 9,126546,DB00497,Oxycodone
,17876144,lag time,"Especially during the absorption process, the lag time was calculated specifically at about 1 hour, making it approximately equal to MS contin.",[Pharmacokinetics of controlled-release oxycodone in patients with cancer pain]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17876144/),h,1,126547,DB00497,Oxycodone
,27558774,MEC,"The analgesic-potency study (n = 50) showed that the median (95% CI) MEC and MEAC were 31.5 (19.2-42.8) and 74.1 (29.2-128.3) ng ml-1 (first measurements) and 63.4 (15.6-120.1) and 76.1 (32.9-132.7) ng ml-1 (second measurements), respectively.",Population pharmacokinetics and analgesic potency of oxycodone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27558774/),[ng] / [ml],31.5,130960,DB00497,Oxycodone
,27558774,MEAC,"The analgesic-potency study (n = 50) showed that the median (95% CI) MEC and MEAC were 31.5 (19.2-42.8) and 74.1 (29.2-128.3) ng ml-1 (first measurements) and 63.4 (15.6-120.1) and 76.1 (32.9-132.7) ng ml-1 (second measurements), respectively.",Population pharmacokinetics and analgesic potency of oxycodone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27558774/),[ng] / [ml],74.1,130961,DB00497,Oxycodone
,27558774,MEAC,"The analgesic-potency study (n = 50) showed that the median (95% CI) MEC and MEAC were 31.5 (19.2-42.8) and 74.1 (29.2-128.3) ng ml-1 (first measurements) and 63.4 (15.6-120.1) and 76.1 (32.9-132.7) ng ml-1 (second measurements), respectively.",Population pharmacokinetics and analgesic potency of oxycodone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27558774/),[ng] / [ml],63.4,130962,DB00497,Oxycodone
,27558774,MEAC,"The analgesic-potency study (n = 50) showed that the median (95% CI) MEC and MEAC were 31.5 (19.2-42.8) and 74.1 (29.2-128.3) ng ml-1 (first measurements) and 63.4 (15.6-120.1) and 76.1 (32.9-132.7) ng ml-1 (second measurements), respectively.",Population pharmacokinetics and analgesic potency of oxycodone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27558774/),[ng] / [ml],76.1,130963,DB00497,Oxycodone
,27558774,MEAC,"In major intra-abdominal open surgery, the MEAC and analgesic potency of oxycodone were 75 ng ml-1 and 60 ng ml-1 , respectively.",Population pharmacokinetics and analgesic potency of oxycodone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27558774/),[ng] / [ml],75,130964,DB00497,Oxycodone
,27558774,analgesic potency,"In major intra-abdominal open surgery, the MEAC and analgesic potency of oxycodone were 75 ng ml-1 and 60 ng ml-1 , respectively.",Population pharmacokinetics and analgesic potency of oxycodone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27558774/),[ng] / [ml],60,130965,DB00497,Oxycodone
,23743505,Recoveries,"Recoveries from plasma were: oxycodone, 75.6%; noroxycodone, 37.4% and oxymorphone, 18.2%.","Determination of oxycodone, noroxycodone and oxymorphone by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry in human matrices: in vivo and in vitro applications. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23743505/),%,75.6,131358,DB00497,Oxycodone
,23743505,Recoveries,"Recoveries from plasma were: oxycodone, 75.6%; noroxycodone, 37.4% and oxymorphone, 18.2%.","Determination of oxycodone, noroxycodone and oxymorphone by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry in human matrices: in vivo and in vitro applications. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23743505/),%,37.4,131359,DB00497,Oxycodone
,23743505,Recoveries,"Recoveries from plasma were: oxycodone, 75.6%; noroxycodone, 37.4% and oxymorphone, 18.2%.","Determination of oxycodone, noroxycodone and oxymorphone by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry in human matrices: in vivo and in vitro applications. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23743505/),%,18.2,131360,DB00497,Oxycodone
,22201184,elimination clearance,"The population estimates of elimination clearance, volume of the central compartment, and the volume of distribution at steady state for a reference individual (male 35 yr, 70 kg, 170 cm) were 51.0 litre h(-1), 134, and 258 litres, respectively.",Oxycodone clearance is markedly reduced with advancing age: a population pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22201184/),[l] / [h],51.0,132389,DB00497,Oxycodone
,22201184,volume of the central compartment,"The population estimates of elimination clearance, volume of the central compartment, and the volume of distribution at steady state for a reference individual (male 35 yr, 70 kg, 170 cm) were 51.0 litre h(-1), 134, and 258 litres, respectively.",Oxycodone clearance is markedly reduced with advancing age: a population pharmacokinetic study. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22201184/),l,134,132390,DB00497,Oxycodone
,22201184,volume of distribution at steady state,"The population estimates of elimination clearance, volume of the central compartment, and the volume of distribution at steady state for a reference individual (male 35 yr, 70 kg, 170 cm) were 51.0 litre h(-1), 134, and 258 litres, respectively.",Oxycodone clearance is markedly reduced with advancing age: a population pharmacokinetic study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22201184/),l,258,132391,DB00497,Oxycodone
,22201184,half-time at steady state,"The context-sensitive half-time at steady state increased from 3.8 to 4.6 h between the age of 25 and 85 yr, respectively.",Oxycodone clearance is markedly reduced with advancing age: a population pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22201184/),h,3.8,132392,DB00497,Oxycodone
,22201184,half-time at steady state,"The context-sensitive half-time at steady state increased from 3.8 to 4.6 h between the age of 25 and 85 yr, respectively.",Oxycodone clearance is markedly reduced with advancing age: a population pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22201184/),h,4.6,132393,DB00497,Oxycodone
,20106684,elimination half-life,Oxycodone elimination half-life shortened from a mean+/-SD 3.8+/-0.7 to 3.0+/-0.4h (p<0.001).,St John's wort greatly reduces the concentrations of oral oxycodone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20106684/),h,3.8,133621,DB00497,Oxycodone
,20106684,elimination half-life,Oxycodone elimination half-life shortened from a mean+/-SD 3.8+/-0.7 to 3.0+/-0.4h (p<0.001).,St John's wort greatly reduces the concentrations of oral oxycodone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20106684/),h,3.0,133622,DB00497,Oxycodone
,23879213,Pain levels,Pain levels before treatment averaged 9.5 ± 0.9 out of 10.,A new model for using quantitative urine testing as a diagnostic tool for oxycodone treatment and compliance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23879213/),,9.5,135573,DB00497,Oxycodone
,34196257,Time of maximum concentration,Time of maximum concentration varied from 30 min to approximately 90 min.,Oral absorption of oxycodone in patients with short bowel syndrome. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34196257/),min,30,142770,DB00497,Oxycodone
,34196257,Time of maximum concentration,Time of maximum concentration varied from 30 min to approximately 90 min.,Oral absorption of oxycodone in patients with short bowel syndrome. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34196257/),min,90,142771,DB00497,Oxycodone
,15650985,t(1/2),The median t(1/2) of oxycodone varied from 5.1 to 5.9 hours.,Pharmacodynamics and pharmacokinetics of high-dose oxycodone infusion during and after coronary artery bypass grafting. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15650985/),h,5.1 to 5.9,144396,DB00497,Oxycodone
,15650985,times to awakening,"The mean times to awakening were 3.8 hours and 7.0 hours in the groups OX 0.5 and 1.0, respectively.",Pharmacodynamics and pharmacokinetics of high-dose oxycodone infusion during and after coronary artery bypass grafting. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15650985/),h,3.8,144397,DB00497,Oxycodone
,15650985,times to awakening,"The mean times to awakening were 3.8 hours and 7.0 hours in the groups OX 0.5 and 1.0, respectively.",Pharmacodynamics and pharmacokinetics of high-dose oxycodone infusion during and after coronary artery bypass grafting. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15650985/),h,7.0,144398,DB00497,Oxycodone
,21472729,K(i),Oxycodone competitively inhibited DPHM uptake with a K(i) value of 106 μM.,Diphenhydramine active uptake at the blood-brain barrier and its interaction with oxycodone in vitro and in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21472729/),μM,106,145692,DB00497,Oxycodone
,21472729,K(i),DPHM also competitively inhibited oxycodone uptake with a K(i) value of 34.7 μM.,Diphenhydramine active uptake at the blood-brain barrier and its interaction with oxycodone in vitro and in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21472729/),μM,34.7,145693,DB00497,Oxycodone
,11210403,AUC,"There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens.",Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210403/),,48.59,147172,DB00497,Oxycodone
,11210403,AUC,"There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens.",Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210403/),,49.9,147173,DB00497,Oxycodone
,11210403,Cmax,"There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens.",Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210403/),,7.73,147174,DB00497,Oxycodone
,11210403,Cmax,"There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens.",Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210403/),,6.6,147175,DB00497,Oxycodone
,11210403,tmax,"There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens.",Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210403/),,1.1,147176,DB00497,Oxycodone
,11210403,tmax,"There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens.",Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210403/),,1.6,147177,DB00497,Oxycodone
,8851456,maximum plasma oxycodone concentrations,"The mean (+/- SD) maximum plasma oxycodone concentrations for CR oxycodone and IR oxycodone were 15.1 +/- 4.7 ng/mL and 15.6 +/- 4.4 ng/mL, respectively.",Steady-state bioavailability of controlled-release oxycodone in normal subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851456/),[ng] / [ml],15.1,151088,DB00497,Oxycodone
,8851456,maximum plasma oxycodone concentrations,"The mean (+/- SD) maximum plasma oxycodone concentrations for CR oxycodone and IR oxycodone were 15.1 +/- 4.7 ng/mL and 15.6 +/- 4.4 ng/mL, respectively.",Steady-state bioavailability of controlled-release oxycodone in normal subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851456/),[ng] / [ml],15.6,151089,DB00497,Oxycodone
,8851456,time to maximum concentration (Tmax),The time to maximum concentration (Tmax) was approximately twice as long for CR oxycodone (3.2 +/- 2.2 hours) as for IR oxycodone (1.4 +/- 0.7 hours) (P = 0.005).,Steady-state bioavailability of controlled-release oxycodone in normal subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851456/),h,3.2,151090,DB00497,Oxycodone
,8851456,time to maximum concentration (Tmax),The time to maximum concentration (Tmax) was approximately twice as long for CR oxycodone (3.2 +/- 2.2 hours) as for IR oxycodone (1.4 +/- 0.7 hours) (P = 0.005).,Steady-state bioavailability of controlled-release oxycodone in normal subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851456/),h,1.4,151091,DB00497,Oxycodone
,8851456,area under the plasma concentration-time curve from 0 to 12 hours at steady state,The area under the plasma concentration-time curve from 0 to 12 hours at steady state was 103.6 +/- 40.0 ng.h/mL for CR oxycodone and 99.0 +/- 35.8 ng.h/mL for IR oxycodone.,Steady-state bioavailability of controlled-release oxycodone in normal subjects. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851456/),[h·ng] / [ml],103.6,151092,DB00497,Oxycodone
,8851456,area under the plasma concentration-time curve from 0 to 12 hours at steady state,The area under the plasma concentration-time curve from 0 to 12 hours at steady state was 103.6 +/- 40.0 ng.h/mL for CR oxycodone and 99.0 +/- 35.8 ng.h/mL for IR oxycodone.,Steady-state bioavailability of controlled-release oxycodone in normal subjects. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851456/),[h·ng] / [ml],99.0,151093,DB00497,Oxycodone
,18473019,elimination half-lives,"The estimated elimination half-lives for morphine and oxycodone were (mean +/- SD) 2.7 +/- 3.6 (range 0.8-11.6) and 3.1 +/- 1.3 (range 1.1-4.8) hr, respectively.",Pharmacokinetics of morphine and oxycodone following intravenous administration in elderly patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18473019/),h,2.7,156692,DB00497,Oxycodone
,18473019,elimination half-lives,"The estimated elimination half-lives for morphine and oxycodone were (mean +/- SD) 2.7 +/- 3.6 (range 0.8-11.6) and 3.1 +/- 1.3 (range 1.1-4.8) hr, respectively.",Pharmacokinetics of morphine and oxycodone following intravenous administration in elderly patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18473019/),h,3.1,156693,DB00497,Oxycodone
,18473019,Volume of distribution at steady state,"Volume of distribution at steady state was estimated to be 243 +/- 256 and 277 +/- 187 L, and clearance to be 1748 +/- 623 and 1206 +/- 546 ml/min for morphine and oxycodone, respectively.",Pharmacokinetics of morphine and oxycodone following intravenous administration in elderly patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18473019/),l,243,156694,DB00497,Oxycodone
,18473019,Volume of distribution at steady state,"Volume of distribution at steady state was estimated to be 243 +/- 256 and 277 +/- 187 L, and clearance to be 1748 +/- 623 and 1206 +/- 546 ml/min for morphine and oxycodone, respectively.",Pharmacokinetics of morphine and oxycodone following intravenous administration in elderly patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18473019/),l,277,156695,DB00497,Oxycodone
,18473019,clearance,"Volume of distribution at steady state was estimated to be 243 +/- 256 and 277 +/- 187 L, and clearance to be 1748 +/- 623 and 1206 +/- 546 ml/min for morphine and oxycodone, respectively.",Pharmacokinetics of morphine and oxycodone following intravenous administration in elderly patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18473019/),[ml] / [min],1748,156696,DB00497,Oxycodone
,18473019,clearance,"Volume of distribution at steady state was estimated to be 243 +/- 256 and 277 +/- 187 L, and clearance to be 1748 +/- 623 and 1206 +/- 546 ml/min for morphine and oxycodone, respectively.",Pharmacokinetics of morphine and oxycodone following intravenous administration in elderly patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18473019/),[ml] / [min],1206,156697,DB00497,Oxycodone
more,18520605,extraction recoveries,"The extraction recoveries were more than 85%, the intraday and interday coefficients of variation were <15%, and the accuracy was >90% for all analytes at relevant plasma concentrations.","Determination of oxycodone, noroxycodone, oxymorphone, and noroxymorphone in human plasma by liquid chromatography-electrospray-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520605/),%,85,162078,DB00497,Oxycodone
,21142269,elimination half-life,"The combination of paroxetine and itraconazole prolonged the mean elimination half-life of oxycodone from 3.8 to 6.6 hours (p < 0.001), and increased the exposure to oxycodone 2-fold (p < 0.001).","Effect of inhibition of cytochrome P450 enzymes 2D6 and 3A4 on the pharmacokinetics of intravenous oxycodone: a randomized, three-phase, crossover, placebo-controlled study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21142269/),h,3.8,164029,DB00497,Oxycodone
,21142269,elimination half-life,"The combination of paroxetine and itraconazole prolonged the mean elimination half-life of oxycodone from 3.8 to 6.6 hours (p < 0.001), and increased the exposure to oxycodone 2-fold (p < 0.001).","Effect of inhibition of cytochrome P450 enzymes 2D6 and 3A4 on the pharmacokinetics of intravenous oxycodone: a randomized, three-phase, crossover, placebo-controlled study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21142269/),h,6,164030,DB00497,Oxycodone
,25901481,Cmax,"Mean (SD) oxycodone Cmax values following Remoxy 20-mg administration were 17.6 (9.1), 21.9 (11.2), 25.9 (18.2), and 31.6 (14.5) ng/mL and AUC0-t values were 210.7 (82.1), 271.6 (83.3), 299.5 (76.3), and 493.5 (175.9) ng·h/mL in subjects with normal or mild (n = 6 each), moderate (n = 5), and severely impaired renal function (n = 6), respectively.","The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25901481/),[ng] / [ml],17.6,164365,DB00497,Oxycodone
,25901481,Cmax,"Mean (SD) oxycodone Cmax values following Remoxy 20-mg administration were 17.6 (9.1), 21.9 (11.2), 25.9 (18.2), and 31.6 (14.5) ng/mL and AUC0-t values were 210.7 (82.1), 271.6 (83.3), 299.5 (76.3), and 493.5 (175.9) ng·h/mL in subjects with normal or mild (n = 6 each), moderate (n = 5), and severely impaired renal function (n = 6), respectively.","The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25901481/),[ng] / [ml],21.9,164366,DB00497,Oxycodone
,25901481,Cmax,"Mean (SD) oxycodone Cmax values following Remoxy 20-mg administration were 17.6 (9.1), 21.9 (11.2), 25.9 (18.2), and 31.6 (14.5) ng/mL and AUC0-t values were 210.7 (82.1), 271.6 (83.3), 299.5 (76.3), and 493.5 (175.9) ng·h/mL in subjects with normal or mild (n = 6 each), moderate (n = 5), and severely impaired renal function (n = 6), respectively.","The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25901481/),[ng] / [ml],25.9,164367,DB00497,Oxycodone
,25901481,Cmax,"Mean (SD) oxycodone Cmax values following Remoxy 20-mg administration were 17.6 (9.1), 21.9 (11.2), 25.9 (18.2), and 31.6 (14.5) ng/mL and AUC0-t values were 210.7 (82.1), 271.6 (83.3), 299.5 (76.3), and 493.5 (175.9) ng·h/mL in subjects with normal or mild (n = 6 each), moderate (n = 5), and severely impaired renal function (n = 6), respectively.","The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25901481/),[ng] / [ml],31.6,164368,DB00497,Oxycodone
,25901481,AUC0-t,"Mean (SD) oxycodone Cmax values following Remoxy 20-mg administration were 17.6 (9.1), 21.9 (11.2), 25.9 (18.2), and 31.6 (14.5) ng/mL and AUC0-t values were 210.7 (82.1), 271.6 (83.3), 299.5 (76.3), and 493.5 (175.9) ng·h/mL in subjects with normal or mild (n = 6 each), moderate (n = 5), and severely impaired renal function (n = 6), respectively.","The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25901481/),[h·ng] / [ml],210.7,164369,DB00497,Oxycodone
,25901481,AUC0-t,"Mean (SD) oxycodone Cmax values following Remoxy 20-mg administration were 17.6 (9.1), 21.9 (11.2), 25.9 (18.2), and 31.6 (14.5) ng/mL and AUC0-t values were 210.7 (82.1), 271.6 (83.3), 299.5 (76.3), and 493.5 (175.9) ng·h/mL in subjects with normal or mild (n = 6 each), moderate (n = 5), and severely impaired renal function (n = 6), respectively.","The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25901481/),[h·ng] / [ml],271.6,164370,DB00497,Oxycodone
,25901481,AUC0-t,"Mean (SD) oxycodone Cmax values following Remoxy 20-mg administration were 17.6 (9.1), 21.9 (11.2), 25.9 (18.2), and 31.6 (14.5) ng/mL and AUC0-t values were 210.7 (82.1), 271.6 (83.3), 299.5 (76.3), and 493.5 (175.9) ng·h/mL in subjects with normal or mild (n = 6 each), moderate (n = 5), and severely impaired renal function (n = 6), respectively.","The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25901481/),[h·ng] / [ml],299.5,164371,DB00497,Oxycodone
,25901481,AUC0-t,"Mean (SD) oxycodone Cmax values following Remoxy 20-mg administration were 17.6 (9.1), 21.9 (11.2), 25.9 (18.2), and 31.6 (14.5) ng/mL and AUC0-t values were 210.7 (82.1), 271.6 (83.3), 299.5 (76.3), and 493.5 (175.9) ng·h/mL in subjects with normal or mild (n = 6 each), moderate (n = 5), and severely impaired renal function (n = 6), respectively.","The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25901481/),[h·ng] / [ml],493.5,164372,DB00497,Oxycodone
,25901481,Cmax,"Mean (SD) oxycodone Cmax following Remoxy 10-mg administration was 7.6 (3.3), 7.8 (2.3), and 13.1 (5.3) ng/mL and AUC(0-t) was 105.7 (49.5), 134.7 (38.3), and 218.0 (74.1) ng·h/mL in subjects with normal, mild, and moderately impaired hepatic function (n = 6 each), respectively.","The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25901481/),[ng] / [ml],7.6,164373,DB00497,Oxycodone
,25901481,Cmax,"Mean (SD) oxycodone Cmax following Remoxy 10-mg administration was 7.6 (3.3), 7.8 (2.3), and 13.1 (5.3) ng/mL and AUC(0-t) was 105.7 (49.5), 134.7 (38.3), and 218.0 (74.1) ng·h/mL in subjects with normal, mild, and moderately impaired hepatic function (n = 6 each), respectively.","The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25901481/),[ng] / [ml],7.8,164374,DB00497,Oxycodone
,25901481,Cmax,"Mean (SD) oxycodone Cmax following Remoxy 10-mg administration was 7.6 (3.3), 7.8 (2.3), and 13.1 (5.3) ng/mL and AUC(0-t) was 105.7 (49.5), 134.7 (38.3), and 218.0 (74.1) ng·h/mL in subjects with normal, mild, and moderately impaired hepatic function (n = 6 each), respectively.","The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25901481/),[ng] / [ml],13.1,164375,DB00497,Oxycodone
,25901481,AUC(0-t),"Mean (SD) oxycodone Cmax following Remoxy 10-mg administration was 7.6 (3.3), 7.8 (2.3), and 13.1 (5.3) ng/mL and AUC(0-t) was 105.7 (49.5), 134.7 (38.3), and 218.0 (74.1) ng·h/mL in subjects with normal, mild, and moderately impaired hepatic function (n = 6 each), respectively.","The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25901481/),[h·ng] / [ml],105.7,164376,DB00497,Oxycodone
,25901481,AUC(0-t),"Mean (SD) oxycodone Cmax following Remoxy 10-mg administration was 7.6 (3.3), 7.8 (2.3), and 13.1 (5.3) ng/mL and AUC(0-t) was 105.7 (49.5), 134.7 (38.3), and 218.0 (74.1) ng·h/mL in subjects with normal, mild, and moderately impaired hepatic function (n = 6 each), respectively.","The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25901481/),[h·ng] / [ml],134.7,164377,DB00497,Oxycodone
,25901481,AUC(0-t),"Mean (SD) oxycodone Cmax following Remoxy 10-mg administration was 7.6 (3.3), 7.8 (2.3), and 13.1 (5.3) ng/mL and AUC(0-t) was 105.7 (49.5), 134.7 (38.3), and 218.0 (74.1) ng·h/mL in subjects with normal, mild, and moderately impaired hepatic function (n = 6 each), respectively.","The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25901481/),[h·ng] / [ml],218.0,164378,DB00497,Oxycodone
>,32486995,bioavailability,For drugs with a high bioavailability (> 70 %) only the impaired hepatic clearance has to be considered.,[Opioid therapy in patients with liver cirrhosis]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32486995/),%,70,167613,DB00497,Oxycodone
>,32486995,bioavailability,"Buprenorphine, fentanyl, hydromorphone, morphine, naloxone und tapentadol are drugs with a high first-pass effect, while the bioavailability of methadone, oxycodone and tramadol is > 70 %.",[Opioid therapy in patients with liver cirrhosis]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32486995/),%,70,167614,DB00497,Oxycodone
,26814256,abuse quotient (Cmax/Tmax),"For primary pharmacokinetic (PK) assessments, abuse quotient (Cmax/Tmax) was lower with DETERx IN than DETERx PO; both treatments were substantially lower than OXY-IR IN (6.24, 8.60, and 69.6 ng/mL/h, respectively).","A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26814256/),[ng] / [h·ml],6.24,172847,DB00497,Oxycodone
,26814256,abuse quotient (Cmax/Tmax),"For primary pharmacokinetic (PK) assessments, abuse quotient (Cmax/Tmax) was lower with DETERx IN than DETERx PO; both treatments were substantially lower than OXY-IR IN (6.24, 8.60, and 69.6 ng/mL/h, respectively).","A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26814256/),[ng] / [h·ml],8.60,172848,DB00497,Oxycodone
,26814256,abuse quotient (Cmax/Tmax),"For primary pharmacokinetic (PK) assessments, abuse quotient (Cmax/Tmax) was lower with DETERx IN than DETERx PO; both treatments were substantially lower than OXY-IR IN (6.24, 8.60, and 69.6 ng/mL/h, respectively).","A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26814256/),[ng] / [h·ml],69.6,172849,DB00497,Oxycodone
,16802855,area under the plasma concentration-time curve from time zero extrapolated to infinity (AUCinfinity),The area under the plasma concentration-time curve from time zero extrapolated to infinity (AUCinfinity) was 2400-8000 ng x min/mL (median 4200 ng x min/mL) in the buccal group and 2700-7900 ng x min/mL (median 5500 ng x min/mL) in the sublingual group.,Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16802855/),[min·ng] / [ml],2400-8000,174308,DB00497,Oxycodone
,16802855,area under the plasma concentration-time curve from time zero extrapolated to infinity (AUCinfinity),The area under the plasma concentration-time curve from time zero extrapolated to infinity (AUCinfinity) was 2400-8000 ng x min/mL (median 4200 ng x min/mL) in the buccal group and 2700-7900 ng x min/mL (median 5500 ng x min/mL) in the sublingual group.,Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16802855/),[min·ng] / [ml],4200,174309,DB00497,Oxycodone
,16802855,area under the plasma concentration-time curve from time zero extrapolated to infinity (AUCinfinity),The area under the plasma concentration-time curve from time zero extrapolated to infinity (AUCinfinity) was 2400-8000 ng x min/mL (median 4200 ng x min/mL) in the buccal group and 2700-7900 ng x min/mL (median 5500 ng x min/mL) in the sublingual group.,Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16802855/),[min·ng] / [ml],2700-7900,174310,DB00497,Oxycodone
,16802855,area under the plasma concentration-time curve from time zero extrapolated to infinity (AUCinfinity),The area under the plasma concentration-time curve from time zero extrapolated to infinity (AUCinfinity) was 2400-8000 ng x min/mL (median 4200 ng x min/mL) in the buccal group and 2700-7900 ng x min/mL (median 5500 ng x min/mL) in the sublingual group.,Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16802855/),[min·ng] / [ml],5500,174311,DB00497,Oxycodone
,16802855,maximum plasma concentration (Cmax),"After buccal administration, maximum plasma concentration (Cmax) was 5.4-39 ng/mL (16 ng/mL) after buccal and 5.5-42 ng/mL (22 ng/mL) after sublingual administration.",Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16802855/),[ng] / [ml],5.4-39,174312,DB00497,Oxycodone
,16802855,maximum plasma concentration (Cmax),"After buccal administration, maximum plasma concentration (Cmax) was 5.4-39 ng/mL (16 ng/mL) after buccal and 5.5-42 ng/mL (22 ng/mL) after sublingual administration.",Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16802855/),[ng] / [ml],5.5-42,174313,DB00497,Oxycodone
,16802855,terminal elimination half-lives,The terminal elimination half-lives were closely similar in the two groups: 104-251 minutes (median 140 minutes) in the buccal group and 110-190 minutes (150 minutes) in the sublingual group.,Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16802855/),min,104-251,174314,DB00497,Oxycodone
,16802855,terminal elimination half-lives,The terminal elimination half-lives were closely similar in the two groups: 104-251 minutes (median 140 minutes) in the buccal group and 110-190 minutes (150 minutes) in the sublingual group.,Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16802855/),min,140,174315,DB00497,Oxycodone
,16802855,terminal elimination half-lives,The terminal elimination half-lives were closely similar in the two groups: 104-251 minutes (median 140 minutes) in the buccal group and 110-190 minutes (150 minutes) in the sublingual group.,Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16802855/),min,110-190,174316,DB00497,Oxycodone
,19108793,AUC(t),"With oxycodone, the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 473.49 (72.16), 491.22 (82.18), 488.89 (91.04), and 502.28 (84.13) ng . h/mL, respectively; mean C(max) values were 34.91 (4.36), 35.73 (4.93), 34.46 (5.03), and 40.45 (4.71) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[h·ng] / [ml],473.49,175280,DB00497,Oxycodone
,19108793,AUC(t),"With oxycodone, the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 473.49 (72.16), 491.22 (82.18), 488.89 (91.04), and 502.28 (84.13) ng . h/mL, respectively; mean C(max) values were 34.91 (4.36), 35.73 (4.93), 34.46 (5.03), and 40.45 (4.71) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[h·ng] / [ml],491.22,175281,DB00497,Oxycodone
,19108793,AUC(t),"With oxycodone, the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 473.49 (72.16), 491.22 (82.18), 488.89 (91.04), and 502.28 (84.13) ng . h/mL, respectively; mean C(max) values were 34.91 (4.36), 35.73 (4.93), 34.46 (5.03), and 40.45 (4.71) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[h·ng] / [ml],488.89,175282,DB00497,Oxycodone
,19108793,AUC(t),"With oxycodone, the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 473.49 (72.16), 491.22 (82.18), 488.89 (91.04), and 502.28 (84.13) ng . h/mL, respectively; mean C(max) values were 34.91 (4.36), 35.73 (4.93), 34.46 (5.03), and 40.45 (4.71) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[h·ng] / [ml],502.28,175283,DB00497,Oxycodone
,19108793,C(max),"With oxycodone, the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 473.49 (72.16), 491.22 (82.18), 488.89 (91.04), and 502.28 (84.13) ng . h/mL, respectively; mean C(max) values were 34.91 (4.36), 35.73 (4.93), 34.46 (5.03), and 40.45 (4.71) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[ng] / [ml],34.91,175284,DB00497,Oxycodone
,19108793,C(max),"With oxycodone, the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 473.49 (72.16), 491.22 (82.18), 488.89 (91.04), and 502.28 (84.13) ng . h/mL, respectively; mean C(max) values were 34.91 (4.36), 35.73 (4.93), 34.46 (5.03), and 40.45 (4.71) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[ng] / [ml],35.73,175285,DB00497,Oxycodone
,19108793,C(max),"With oxycodone, the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 473.49 (72.16), 491.22 (82.18), 488.89 (91.04), and 502.28 (84.13) ng . h/mL, respectively; mean C(max) values were 34.91 (4.36), 35.73 (4.93), 34.46 (5.03), and 40.45 (4.71) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[ng] / [ml],34.46,175286,DB00497,Oxycodone
,19108793,C(max),"With oxycodone, the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 473.49 (72.16), 491.22 (82.18), 488.89 (91.04), and 502.28 (84.13) ng . h/mL, respectively; mean C(max) values were 34.91 (4.36), 35.73 (4.93), 34.46 (5.03), and 40.45 (4.71) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[ng] / [ml],40.45,175287,DB00497,Oxycodone
,19108793,AUC(t),"For naloxone-3-glucuronide (the primary analyte of naloxone), the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 539.93 (142.24), 522.45 (128.57), 520.10 (133.18), and 523.37 (119.75) ng . h/mL, respectively; mean C(max) values were 62.01 (15.96), 63.62 (19.51), 61.95 (18.37), and 63.55 (16.75) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[h·ng] / [ml],539.93,175288,DB00497,Oxycodone
,19108793,AUC(t),"For naloxone-3-glucuronide (the primary analyte of naloxone), the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 539.93 (142.24), 522.45 (128.57), 520.10 (133.18), and 523.37 (119.75) ng . h/mL, respectively; mean C(max) values were 62.01 (15.96), 63.62 (19.51), 61.95 (18.37), and 63.55 (16.75) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[h·ng] / [ml],522.45,175289,DB00497,Oxycodone
,19108793,AUC(t),"For naloxone-3-glucuronide (the primary analyte of naloxone), the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 539.93 (142.24), 522.45 (128.57), 520.10 (133.18), and 523.37 (119.75) ng . h/mL, respectively; mean C(max) values were 62.01 (15.96), 63.62 (19.51), 61.95 (18.37), and 63.55 (16.75) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[h·ng] / [ml],520.10,175290,DB00497,Oxycodone
,19108793,AUC(t),"For naloxone-3-glucuronide (the primary analyte of naloxone), the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 539.93 (142.24), 522.45 (128.57), 520.10 (133.18), and 523.37 (119.75) ng . h/mL, respectively; mean C(max) values were 62.01 (15.96), 63.62 (19.51), 61.95 (18.37), and 63.55 (16.75) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[h·ng] / [ml],523.37,175291,DB00497,Oxycodone
,19108793,C(max),"For naloxone-3-glucuronide (the primary analyte of naloxone), the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 539.93 (142.24), 522.45 (128.57), 520.10 (133.18), and 523.37 (119.75) ng . h/mL, respectively; mean C(max) values were 62.01 (15.96), 63.62 (19.51), 61.95 (18.37), and 63.55 (16.75) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[ng] / [ml],62.01,175292,DB00497,Oxycodone
,19108793,C(max),"For naloxone-3-glucuronide (the primary analyte of naloxone), the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 539.93 (142.24), 522.45 (128.57), 520.10 (133.18), and 523.37 (119.75) ng . h/mL, respectively; mean C(max) values were 62.01 (15.96), 63.62 (19.51), 61.95 (18.37), and 63.55 (16.75) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[ng] / [ml],63.62,175293,DB00497,Oxycodone
,19108793,C(max),"For naloxone-3-glucuronide (the primary analyte of naloxone), the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 539.93 (142.24), 522.45 (128.57), 520.10 (133.18), and 523.37 (119.75) ng . h/mL, respectively; mean C(max) values were 62.01 (15.96), 63.62 (19.51), 61.95 (18.37), and 63.55 (16.75) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[ng] / [ml],61.95,175294,DB00497,Oxycodone
,19108793,C(max),"For naloxone-3-glucuronide (the primary analyte of naloxone), the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 539.93 (142.24), 522.45 (128.57), 520.10 (133.18), and 523.37 (119.75) ng . h/mL, respectively; mean C(max) values were 62.01 (15.96), 63.62 (19.51), 61.95 (18.37), and 63.55 (16.75) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[ng] / [ml],63.55,175295,DB00497,Oxycodone
,19108793,"C(min,ss)","Mean C(min,ss) values of 22.6 and 24.0 ng/mL were obtained for the OXN combination and naloxone PR tablet, respectively.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[ng] / [ml],22.6,175296,DB00497,Oxycodone
,19108793,"C(min,ss)","Mean C(min,ss) values of 22.6 and 24.0 ng/mL were obtained for the OXN combination and naloxone PR tablet, respectively.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[ng] / [ml],24.0,175297,DB00497,Oxycodone
,12162476,AUC,"No significant difference was noted (p > 0.05) in AUC (31.6 +/- 7.3 vs. 31.7 +/- 7.1) and Cmax (3.2 +/- 0.6 vs. 3.0 +/- 0.6) for gatifloxacin versus gatifloxacin/oxycodone regimens; however, the tmax (1.8 +/- 0.8 vs. 4.3 +/- 1.5) was significantly delayed (p < 0.001).",Minimal interaction between gatifloxacin and oxycodone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12162476/),,31.6,176468,DB00497,Oxycodone
,12162476,AUC,"No significant difference was noted (p > 0.05) in AUC (31.6 +/- 7.3 vs. 31.7 +/- 7.1) and Cmax (3.2 +/- 0.6 vs. 3.0 +/- 0.6) for gatifloxacin versus gatifloxacin/oxycodone regimens; however, the tmax (1.8 +/- 0.8 vs. 4.3 +/- 1.5) was significantly delayed (p < 0.001).",Minimal interaction between gatifloxacin and oxycodone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12162476/),,31.7,176469,DB00497,Oxycodone
,12162476,Cmax,"No significant difference was noted (p > 0.05) in AUC (31.6 +/- 7.3 vs. 31.7 +/- 7.1) and Cmax (3.2 +/- 0.6 vs. 3.0 +/- 0.6) for gatifloxacin versus gatifloxacin/oxycodone regimens; however, the tmax (1.8 +/- 0.8 vs. 4.3 +/- 1.5) was significantly delayed (p < 0.001).",Minimal interaction between gatifloxacin and oxycodone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12162476/),,3.2,176470,DB00497,Oxycodone
,12162476,Cmax,"No significant difference was noted (p > 0.05) in AUC (31.6 +/- 7.3 vs. 31.7 +/- 7.1) and Cmax (3.2 +/- 0.6 vs. 3.0 +/- 0.6) for gatifloxacin versus gatifloxacin/oxycodone regimens; however, the tmax (1.8 +/- 0.8 vs. 4.3 +/- 1.5) was significantly delayed (p < 0.001).",Minimal interaction between gatifloxacin and oxycodone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12162476/),,3.0,176471,DB00497,Oxycodone
,12162476,tmax,"No significant difference was noted (p > 0.05) in AUC (31.6 +/- 7.3 vs. 31.7 +/- 7.1) and Cmax (3.2 +/- 0.6 vs. 3.0 +/- 0.6) for gatifloxacin versus gatifloxacin/oxycodone regimens; however, the tmax (1.8 +/- 0.8 vs. 4.3 +/- 1.5) was significantly delayed (p < 0.001).",Minimal interaction between gatifloxacin and oxycodone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12162476/),,1.8,176472,DB00497,Oxycodone
,12162476,tmax,"No significant difference was noted (p > 0.05) in AUC (31.6 +/- 7.3 vs. 31.7 +/- 7.1) and Cmax (3.2 +/- 0.6 vs. 3.0 +/- 0.6) for gatifloxacin versus gatifloxacin/oxycodone regimens; however, the tmax (1.8 +/- 0.8 vs. 4.3 +/- 1.5) was significantly delayed (p < 0.001).",Minimal interaction between gatifloxacin and oxycodone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12162476/),,4.3,176473,DB00497,Oxycodone
,15692141,maximum APAP concentration ([APAP](max)),"For APAP alone, the mean parameters were: maximum APAP concentration ([APAP](max)) 71.8 microg/mL, time to peak [APAP] (t(max)) 1.71 hours, and area under the receiver operating characteristic curve (AUC(0-8)) 318.3 microg-hr/mL.",Pharmacokinetic effects of diphenhydramine or oxycodone in simulated acetaminophen overdose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692141/),[μg] / [ml],71.8,186083,DB00497,Oxycodone
,15692141,time to peak [APAP] (t(max)),"For APAP alone, the mean parameters were: maximum APAP concentration ([APAP](max)) 71.8 microg/mL, time to peak [APAP] (t(max)) 1.71 hours, and area under the receiver operating characteristic curve (AUC(0-8)) 318.3 microg-hr/mL.",Pharmacokinetic effects of diphenhydramine or oxycodone in simulated acetaminophen overdose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692141/),h,1.71,186084,DB00497,Oxycodone
,15692141,area under the receiver operating characteristic curve (AUC(0-8)),"For APAP alone, the mean parameters were: maximum APAP concentration ([APAP](max)) 71.8 microg/mL, time to peak [APAP] (t(max)) 1.71 hours, and area under the receiver operating characteristic curve (AUC(0-8)) 318.3 microg-hr/mL.",Pharmacokinetic effects of diphenhydramine or oxycodone in simulated acetaminophen overdose. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692141/),[μg-hr] / [ml],318.3,186085,DB00497,Oxycodone
,15692141,t(max),"For APAP+DPH, the mean parameters were: [APAP](max) 67.6 microg/mL, t(max) 1.90 hours, and AUC(0-8) 297.7 microg-hr/mL.",Pharmacokinetic effects of diphenhydramine or oxycodone in simulated acetaminophen overdose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692141/),h,1.90,186086,DB00497,Oxycodone
,15692141,AUC(0-8),"For APAP+DPH, the mean parameters were: [APAP](max) 67.6 microg/mL, t(max) 1.90 hours, and AUC(0-8) 297.7 microg-hr/mL.",Pharmacokinetic effects of diphenhydramine or oxycodone in simulated acetaminophen overdose. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692141/),[μg-hr] / [ml],297.7,186087,DB00497,Oxycodone
,15692141,t(max),"For APAP+OXY, the parameters were: [APAP](max) 42.9 microg/mL, t(max) 2.87 hours, and AUC(0-8) 232.1 microg-hr/mL.",Pharmacokinetic effects of diphenhydramine or oxycodone in simulated acetaminophen overdose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692141/),h,2.87,186088,DB00497,Oxycodone
,15692141,AUC(0-8),"For APAP+OXY, the parameters were: [APAP](max) 42.9 microg/mL, t(max) 2.87 hours, and AUC(0-8) 232.1 microg-hr/mL.",Pharmacokinetic effects of diphenhydramine or oxycodone in simulated acetaminophen overdose. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692141/),[μg-hr] / [ml],232.1,186089,DB00497,Oxycodone
,31597014,absorption lag,The controlled-release formulations had an absorption lag of 0.23 hour and a slower absorption rate constant (kaCR = 0.19 hour-1 ) compared to the oral solution (kaSOL = 0.94 hour-1 ).,Population pharmacokinetic-pharmacodynamic modelling of liquid and controlled-release formulations of oxycodone in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31597014/),h,0.23,187251,DB00497,Oxycodone
,31597014,absorption rate constant (kaCR,The controlled-release formulations had an absorption lag of 0.23 hour and a slower absorption rate constant (kaCR = 0.19 hour-1 ) compared to the oral solution (kaSOL = 0.94 hour-1 ).,Population pharmacokinetic-pharmacodynamic modelling of liquid and controlled-release formulations of oxycodone in healthy volunteers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31597014/),1/[h],0.19,187252,DB00497,Oxycodone
,31597014,kaSOL,The controlled-release formulations had an absorption lag of 0.23 hour and a slower absorption rate constant (kaCR = 0.19 hour-1 ) compared to the oral solution (kaSOL = 0.94 hour-1 ).,Population pharmacokinetic-pharmacodynamic modelling of liquid and controlled-release formulations of oxycodone in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31597014/),1/[h],0.94,187253,DB00497,Oxycodone
,31597014,half-life,Effects on pupil diameter were delayed relative to plasma (14 minutes half-life) for all formulations and were best described by a proportional Emax model.,Population pharmacokinetic-pharmacodynamic modelling of liquid and controlled-release formulations of oxycodone in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31597014/),min,14,187254,DB00497,Oxycodone
,31597014,plasma concentration of o,The plasma concentration of oxycodone at half-maximum effect was lower in males (31.1 μg/L) compared to females (52.8 μg/L; P < .001).,Population pharmacokinetic-pharmacodynamic modelling of liquid and controlled-release formulations of oxycodone in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31597014/),[μg] / [l],31.1,187255,DB00497,Oxycodone
,31597014,plasma concentration of o,The plasma concentration of oxycodone at half-maximum effect was lower in males (31.1 μg/L) compared to females (52.8 μg/L; P < .001).,Population pharmacokinetic-pharmacodynamic modelling of liquid and controlled-release formulations of oxycodone in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31597014/),[μg] / [l],52.8,187256,DB00497,Oxycodone
,23677743,C max,Mean C max values for finely crushed ORF (17.1 ng/mL) and coarsely crushed ORF (15.5 ng/mL) were lower than that for finely crushed OC (22.2 ng/mL).,"Pharmacokinetics, tolerability, and safety of intranasal administration of reformulated OxyContin(®) tablets compared with original OxyContin (®) tablets in healthy adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23677743/),[ng] / [ml],17.1,188412,DB00497,Oxycodone
,23677743,C max,Mean C max values for finely crushed ORF (17.1 ng/mL) and coarsely crushed ORF (15.5 ng/mL) were lower than that for finely crushed OC (22.2 ng/mL).,"Pharmacokinetics, tolerability, and safety of intranasal administration of reformulated OxyContin(®) tablets compared with original OxyContin (®) tablets in healthy adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23677743/),[ng] / [ml],15.5,188413,DB00497,Oxycodone
,23677743,C max,Mean C max values for finely crushed ORF (17.1 ng/mL) and coarsely crushed ORF (15.5 ng/mL) were lower than that for finely crushed OC (22.2 ng/mL).,"Pharmacokinetics, tolerability, and safety of intranasal administration of reformulated OxyContin(®) tablets compared with original OxyContin (®) tablets in healthy adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23677743/),[ng] / [ml],22.2,188414,DB00497,Oxycodone
,23677743,t max,Median t max for finely crushed OC (1.0 h) was shorter than that for either finely crushed ORF (2.0 h) or coarsely crushed ORF (3.0 h).,"Pharmacokinetics, tolerability, and safety of intranasal administration of reformulated OxyContin(®) tablets compared with original OxyContin (®) tablets in healthy adults. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23677743/),h,1.0,188415,DB00497,Oxycodone
,23677743,t max,Median t max for finely crushed OC (1.0 h) was shorter than that for either finely crushed ORF (2.0 h) or coarsely crushed ORF (3.0 h).,"Pharmacokinetics, tolerability, and safety of intranasal administration of reformulated OxyContin(®) tablets compared with original OxyContin (®) tablets in healthy adults. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23677743/),h,2.0,188416,DB00497,Oxycodone
,23677743,t max,Median t max for finely crushed OC (1.0 h) was shorter than that for either finely crushed ORF (2.0 h) or coarsely crushed ORF (3.0 h).,"Pharmacokinetics, tolerability, and safety of intranasal administration of reformulated OxyContin(®) tablets compared with original OxyContin (®) tablets in healthy adults. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23677743/),h,3.0,188417,DB00497,Oxycodone
,22451244,Clearance,"Clearance of the intravenous injections was 28.9 L/h; the volume of distribution at steady state and the half-life of elimination were 186 L and 5.2 h, respectively.",Absorption of different oral dosage forms of oxycodone in the elderly: a cross-over clinical trial in patients undergoing cystoscopy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22451244/),[l] / [h],28.9,189233,DB00497,Oxycodone
,22451244,volume of distribution at steady state,"Clearance of the intravenous injections was 28.9 L/h; the volume of distribution at steady state and the half-life of elimination were 186 L and 5.2 h, respectively.",Absorption of different oral dosage forms of oxycodone in the elderly: a cross-over clinical trial in patients undergoing cystoscopy. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22451244/),l,186,189234,DB00497,Oxycodone
,22451244,half-life of elimination,"Clearance of the intravenous injections was 28.9 L/h; the volume of distribution at steady state and the half-life of elimination were 186 L and 5.2 h, respectively.",Absorption of different oral dosage forms of oxycodone in the elderly: a cross-over clinical trial in patients undergoing cystoscopy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22451244/),h,5.2,189235,DB00497,Oxycodone
,22451244,absolute bioavailability,"The absolute bioavailability of oxycodone was 59 % from oral solutions, 64 % from capsules, and 55 % from controlled-release tablets.",Absorption of different oral dosage forms of oxycodone in the elderly: a cross-over clinical trial in patients undergoing cystoscopy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22451244/),%,59,189236,DB00497,Oxycodone
,22451244,absolute bioavailability,"The absolute bioavailability of oxycodone was 59 % from oral solutions, 64 % from capsules, and 55 % from controlled-release tablets.",Absorption of different oral dosage forms of oxycodone in the elderly: a cross-over clinical trial in patients undergoing cystoscopy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22451244/),%,64,189237,DB00497,Oxycodone
,22451244,absolute bioavailability,"The absolute bioavailability of oxycodone was 59 % from oral solutions, 64 % from capsules, and 55 % from controlled-release tablets.",Absorption of different oral dosage forms of oxycodone in the elderly: a cross-over clinical trial in patients undergoing cystoscopy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22451244/),%,55,189238,DB00497,Oxycodone
,7605420,drug clearance,2. Mean (+/- s.d.) values of drug clearance and volume of distribution (Vss) were 15.2 +/- 4.2 ml min-1 kg-1 and 2.1 +/- 0.8 l kg-1.,Pharmacokinetics and ventilatory effects of intravenous oxycodone in postoperative children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7605420/),[ml] / [kg·min],15.2,192431,DB00497,Oxycodone
,7605420,volume of distribution (Vss),2. Mean (+/- s.d.) values of drug clearance and volume of distribution (Vss) were 15.2 +/- 4.2 ml min-1 kg-1 and 2.1 +/- 0.8 l kg-1.,Pharmacokinetics and ventilatory effects of intravenous oxycodone in postoperative children. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7605420/),[l] / [kg],2.1,192432,DB00497,Oxycodone
,31092024,plasma clearance,"The population parameters for plasma clearance and apparent distribution volumes for central and peripheral compartments for plasma and CSF were 37.4 L/h, 90.2 L, 68.9 L, 0.035 L (fixed based on literature), and 0.039 L, respectively.",Population pharmacokinetics of oxycodone in plasma and cerebrospinal fluid after epidural and intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31092024/),[l] / [h],37.4,196345,DB00497,Oxycodone
,31092024,apparent distribution volumes,"The population parameters for plasma clearance and apparent distribution volumes for central and peripheral compartments for plasma and CSF were 37.4 L/h, 90.2 L, 68.9 L, 0.035 L (fixed based on literature), and 0.039 L, respectively.",Population pharmacokinetics of oxycodone in plasma and cerebrospinal fluid after epidural and intravenous administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31092024/),l,0.035,196346,DB00497,Oxycodone
,31092024,apparent distribution volumes,"The population parameters for plasma clearance and apparent distribution volumes for central and peripheral compartments for plasma and CSF were 37.4 L/h, 90.2 L, 68.9 L, 0.035 L (fixed based on literature), and 0.039 L, respectively.",Population pharmacokinetics of oxycodone in plasma and cerebrospinal fluid after epidural and intravenous administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31092024/),l,0.039,196347,DB00497,Oxycodone
,19417618,Oral bioavailability,Oral bioavailability of oxycodone was decreased from 69% to 21% (P < 0.001).,Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19417618/),%,69,198466,DB00497,Oxycodone
,19417618,Oral bioavailability,Oral bioavailability of oxycodone was decreased from 69% to 21% (P < 0.001).,Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19417618/),%,21,198467,DB00497,Oxycodone
,16584154,C(max),"Following administration of a 0.1 mg dose, the average C(max) values were found to be 64.9 +/- 12.1 and 95.2 +/- 10.1 ng/mL, for pH 4.0 and 9.0, respectively.",Effect of pH on sublingual absorption of oxycodone hydrochloride. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584154/),[ng] / [ml],64.9,204292,DB00497,Oxycodone
,16584154,C(max),"Following administration of a 0.1 mg dose, the average C(max) values were found to be 64.9 +/- 12.1 and 95.2 +/- 10.1 ng/mL, for pH 4.0 and 9.0, respectively.",Effect of pH on sublingual absorption of oxycodone hydrochloride. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584154/),[ng] / [ml],95.2,204293,DB00497,Oxycodone
,16584154,area under the curve (AUC),"The area under the curve (AUC) values were found to be 5807.0, and 8965.3 ng.",Effect of pH on sublingual absorption of oxycodone hydrochloride. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584154/),ng,5807.0,204294,DB00497,Oxycodone
,16584154,area under the curve (AUC),"The area under the curve (AUC) values were found to be 5807.0, and 8965.3 ng.",Effect of pH on sublingual absorption of oxycodone hydrochloride. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584154/),ng,8965.3,204295,DB00497,Oxycodone
,16584154,bioavailability,"The mean sublingual bioavailability of oxycodone was 45.4% +/- 20.1% and 70.1% +/- 17.9%, for pH 4.0 and 9.0, respectively.",Effect of pH on sublingual absorption of oxycodone hydrochloride. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584154/),%,45.4,204296,DB00497,Oxycodone
,16584154,bioavailability,"The mean sublingual bioavailability of oxycodone was 45.4% +/- 20.1% and 70.1% +/- 17.9%, for pH 4.0 and 9.0, respectively.",Effect of pH on sublingual absorption of oxycodone hydrochloride. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584154/),%,70.1,204297,DB00497,Oxycodone
,32486875,plasma elimination half-life,Mean plasma elimination half-life is 13 hours and bioavailability 47-57% after the first sublingual sufentanil tablet.,An up-to-date overview of sublingual sufentanil for the treatment of moderate to severe pain. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32486875/),h,13,204667,DB00497,Oxycodone
,32486875,bioavailability,Mean plasma elimination half-life is 13 hours and bioavailability 47-57% after the first sublingual sufentanil tablet.,An up-to-date overview of sublingual sufentanil for the treatment of moderate to severe pain. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32486875/),%,47-57,204668,DB00497,Oxycodone
,20697700,elimination half-life,"The mean (± SD) elimination half-life increased after ritonavir and lopinavir/ritonavir from 3.6 ± 0.6 to 5.6 ± 0.9 h (P <0.001) and 5.7 ± 0.9 h (P <0.001), respectively.",Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20697700/),h,3.6,204950,DB00497,Oxycodone
,20697700,elimination half-life,"The mean (± SD) elimination half-life increased after ritonavir and lopinavir/ritonavir from 3.6 ± 0.6 to 5.6 ± 0.9 h (P <0.001) and 5.7 ± 0.9 h (P <0.001), respectively.",Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20697700/),h,5.6,204951,DB00497,Oxycodone
,20697700,elimination half-life,"The mean (± SD) elimination half-life increased after ritonavir and lopinavir/ritonavir from 3.6 ± 0.6 to 5.6 ± 0.9 h (P <0.001) and 5.7 ± 0.9 h (P <0.001), respectively.",Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20697700/),h,5.7,204952,DB00497,Oxycodone
,2053119,detection limit,"An original, highly sensitive and specific high-performance liquid chromatographic (HPLC) assay has been developed for the measurement of oxycodone in human plasma with a detection limit of 10 ng/ml using a 1.0-ml plasma sample.",Quantitation of oxycodone in human plasma using high-performance liquid chromatography with electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2053119/),[ng] / [ml],10,208051,DB00497,Oxycodone
,22717418,C(max),"The bioavailability of oxycodone from IRO-A tablets in the fed state was comparable with IRO tablets based on AUC parameters, although C(max) was ~16.5% lower.","Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22717418/),%,16.5,210871,DB00497,Oxycodone
,28421874,maximum plasma concentration,"Oxycodone was detected 8.0 ± 2.7-h postpatch administration, reaching a mean maximum plasma concentration of 3.41 ± 1.34 ng/ml at 49.3 ± 21.2 h.","Pharmacokinetics, safety and tolerability of a novel tocopheryl phosphate mixture/oxycodone transdermal patch system: a Phase I study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28421874/),[ng] / [ml],3.41,212221,DB00497,Oxycodone
,24077699,clearance,"Typical population values and between-subject variability (coefficient of variation, percent) for oxycodone clearance and the oral absorption rate constant were 73 L/h (31.9 %) and 0.0735 h (133 %), respectively.",Should the dosage of controlled-release oxycodone in advanced cancer be modified on the basis of patient characteristics? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24077699/),[l] / [h],73,214433,DB00497,Oxycodone
,24077699,oral absorption rate constant,"Typical population values and between-subject variability (coefficient of variation, percent) for oxycodone clearance and the oral absorption rate constant were 73 L/h (31.9 %) and 0.0735 h (133 %), respectively.",Should the dosage of controlled-release oxycodone in advanced cancer be modified on the basis of patient characteristics? ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24077699/),h,0.0735,214434,DB00497,Oxycodone
,28345745,conversion to OC,Incubation at 80°C for 24 hours in vinegar or vodka produced a conversion to OC of 6 percent.,"In vitro and in vivo assessment of the abuse potential of PF614, a novel BIO-MD™ prodrug of oxycodone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28345745/),%,6,219178,DB00497,Oxycodone
,28345745,half-life,Incubation with trypsin at 37°C converted PF614 approximately stoichiometric to OC with half-life of 4 hours.,"In vitro and in vivo assessment of the abuse potential of PF614, a novel BIO-MD™ prodrug of oxycodone. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28345745/),h,4,219179,DB00497,Oxycodone
,10984808,clearance,"Mean population pharmacokinetic values of 0.407 L/hr/kg for clearance, 4.0 L/kg for volume of distribution, 31% for bioavailability, and 10.6 hours for half-life were determined on the basis of 569 blood cyclosporine levels.",Cyclosporine-drug interactions and the influence of patient age. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984808/),[l] / [h·kg],0.407,223254,DB00497,Oxycodone
,10984808,volume of distribution,"Mean population pharmacokinetic values of 0.407 L/hr/kg for clearance, 4.0 L/kg for volume of distribution, 31% for bioavailability, and 10.6 hours for half-life were determined on the basis of 569 blood cyclosporine levels.",Cyclosporine-drug interactions and the influence of patient age. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984808/),[l] / [kg],4.0,223255,DB00497,Oxycodone
,10984808,bioavailability,"Mean population pharmacokinetic values of 0.407 L/hr/kg for clearance, 4.0 L/kg for volume of distribution, 31% for bioavailability, and 10.6 hours for half-life were determined on the basis of 569 blood cyclosporine levels.",Cyclosporine-drug interactions and the influence of patient age. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984808/),%,31,223256,DB00497,Oxycodone
,10984808,half-life,"Mean population pharmacokinetic values of 0.407 L/hr/kg for clearance, 4.0 L/kg for volume of distribution, 31% for bioavailability, and 10.6 hours for half-life were determined on the basis of 569 blood cyclosporine levels.",Cyclosporine-drug interactions and the influence of patient age. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984808/),h,10.6,223257,DB00497,Oxycodone
,15960639,clearance (Cl),"The median (range) values for the clearance (Cl) were 9.9 (2.3-17.2), 20.1 (3.7-40.4) and 15.4 (14.8-80.2) ml.min(-1).",Marked variation in oxycodone pharmacokinetics in infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15960639/),[ml] / [min],9.9,225461,DB00497,Oxycodone
,15960639,clearance (Cl),"The median (range) values for the clearance (Cl) were 9.9 (2.3-17.2), 20.1 (3.7-40.4) and 15.4 (14.8-80.2) ml.min(-1).",Marked variation in oxycodone pharmacokinetics in infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15960639/),[ml] / [min],20.1,225462,DB00497,Oxycodone
,15960639,clearance (Cl),"The median (range) values for the clearance (Cl) were 9.9 (2.3-17.2), 20.1 (3.7-40.4) and 15.4 (14.8-80.2) ml.min(-1).",Marked variation in oxycodone pharmacokinetics in infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15960639/),[ml] / [min],15.4,225463,DB00497,Oxycodone
,15960639,volume of distribution at steady-state,"The values for volume of distribution at steady-state were 3.3 (1.9-4.7), 5.6 (1.3-8.5) and 3.2 (1.8-6.0) l.kg(-1) and for elimination half-life (t(1/2)) 4.4 (2.4-14.1), 3.6 (1.6-11.6) and 2.0 (0.8-3.9) h, respectively.",Marked variation in oxycodone pharmacokinetics in infants. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15960639/),[l] / [kg],3.3,225464,DB00497,Oxycodone
,15960639,volume of distribution at steady-state,"The values for volume of distribution at steady-state were 3.3 (1.9-4.7), 5.6 (1.3-8.5) and 3.2 (1.8-6.0) l.kg(-1) and for elimination half-life (t(1/2)) 4.4 (2.4-14.1), 3.6 (1.6-11.6) and 2.0 (0.8-3.9) h, respectively.",Marked variation in oxycodone pharmacokinetics in infants. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15960639/),[l] / [kg],5.6,225465,DB00497,Oxycodone
,15960639,volume of distribution at steady-state,"The values for volume of distribution at steady-state were 3.3 (1.9-4.7), 5.6 (1.3-8.5) and 3.2 (1.8-6.0) l.kg(-1) and for elimination half-life (t(1/2)) 4.4 (2.4-14.1), 3.6 (1.6-11.6) and 2.0 (0.8-3.9) h, respectively.",Marked variation in oxycodone pharmacokinetics in infants. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15960639/),[l] / [kg],3.2,225466,DB00497,Oxycodone
,15960639,elimination half-life (t(1/2)),"The values for volume of distribution at steady-state were 3.3 (1.9-4.7), 5.6 (1.3-8.5) and 3.2 (1.8-6.0) l.kg(-1) and for elimination half-life (t(1/2)) 4.4 (2.4-14.1), 3.6 (1.6-11.6) and 2.0 (0.8-3.9) h, respectively.",Marked variation in oxycodone pharmacokinetics in infants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15960639/),h,4.4,225467,DB00497,Oxycodone
,15960639,elimination half-life (t(1/2)),"The values for volume of distribution at steady-state were 3.3 (1.9-4.7), 5.6 (1.3-8.5) and 3.2 (1.8-6.0) l.kg(-1) and for elimination half-life (t(1/2)) 4.4 (2.4-14.1), 3.6 (1.6-11.6) and 2.0 (0.8-3.9) h, respectively.",Marked variation in oxycodone pharmacokinetics in infants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15960639/),h,3.6,225468,DB00497,Oxycodone
,15960639,elimination half-life (t(1/2)),"The values for volume of distribution at steady-state were 3.3 (1.9-4.7), 5.6 (1.3-8.5) and 3.2 (1.8-6.0) l.kg(-1) and for elimination half-life (t(1/2)) 4.4 (2.4-14.1), 3.6 (1.6-11.6) and 2.0 (0.8-3.9) h, respectively.",Marked variation in oxycodone pharmacokinetics in infants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15960639/),h,2.0,225469,DB00497,Oxycodone
,33515201,half maximal inhibitory concentration (IC50),"The PK/PD model parameters were confirmed by the new data, leading to the following estimates: half maximal inhibitory concentration (IC50) of 26.5 ng/mL, maximum pupil restriction of 66.0% from baseline, and a Hill factor of 1.05.",Oxycodone Effect on Pupil Constriction in Recreational Opioid Users: A Pharmacokinetic/Pharmacodynamic Meta-Analysis Approach. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33515201/),[ng] / [ml],26.5,226249,DB00497,Oxycodone
,33515201,Hill factor,"The PK/PD model parameters were confirmed by the new data, leading to the following estimates: half maximal inhibitory concentration (IC50) of 26.5 ng/mL, maximum pupil restriction of 66.0% from baseline, and a Hill factor of 1.05.",Oxycodone Effect on Pupil Constriction in Recreational Opioid Users: A Pharmacokinetic/Pharmacodynamic Meta-Analysis Approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33515201/),,1.05,226250,DB00497,Oxycodone
,7818116,terminal half-life,"After single-dose intravenous administration (7.9 +/- 1.5 mg, mean +/- SD), the mean (+/- SD) terminal half-life was 3.4 h (+/- 1.1), the mean (+/- SD) plasma clearance was 45.4 L/h (+/- 10.1), and the mean (+/- SD) volume of distribution in the terminal phase was 3.0 L/kg (+/- 1.1).",Pharmacokinetics and pharmacodynamics of oxycodone when given intravenously and rectally to adult patients with cancer pain. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7818116/),h,3.4,227635,DB00497,Oxycodone
,7818116,plasma clearance,"After single-dose intravenous administration (7.9 +/- 1.5 mg, mean +/- SD), the mean (+/- SD) terminal half-life was 3.4 h (+/- 1.1), the mean (+/- SD) plasma clearance was 45.4 L/h (+/- 10.1), and the mean (+/- SD) volume of distribution in the terminal phase was 3.0 L/kg (+/- 1.1).",Pharmacokinetics and pharmacodynamics of oxycodone when given intravenously and rectally to adult patients with cancer pain. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7818116/),[l] / [h],45.4,227636,DB00497,Oxycodone
,7818116,volume of distribution in the terminal phase,"After single-dose intravenous administration (7.9 +/- 1.5 mg, mean +/- SD), the mean (+/- SD) terminal half-life was 3.4 h (+/- 1.1), the mean (+/- SD) plasma clearance was 45.4 L/h (+/- 10.1), and the mean (+/- SD) volume of distribution in the terminal phase was 3.0 L/kg (+/- 1.1).",Pharmacokinetics and pharmacodynamics of oxycodone when given intravenously and rectally to adult patients with cancer pain. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7818116/),[l] / [kg],3.0,227637,DB00497,Oxycodone
,7818116,absorption lag time,"After rectal oxycodone (30 mg), the mean (+/- SD) absorption lag time was 0.52 h (+/- 0.29) and the mean (+/- SD) absolute bioavailability was 61.6% (+/- 30.2%).",Pharmacokinetics and pharmacodynamics of oxycodone when given intravenously and rectally to adult patients with cancer pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7818116/),h,0.52,227638,DB00497,Oxycodone
,7818116,absolute bioavailability,"After rectal oxycodone (30 mg), the mean (+/- SD) absorption lag time was 0.52 h (+/- 0.29) and the mean (+/- SD) absolute bioavailability was 61.6% (+/- 30.2%).",Pharmacokinetics and pharmacodynamics of oxycodone when given intravenously and rectally to adult patients with cancer pain. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7818116/),%,61.6,227639,DB00497,Oxycodone
,11361046,pain intensity,Mean (+/- SD) pain intensity (0 = none to 10 = severe) decreased from a baseline of 6.0 +/- 2.2 to 2.7 +/- 1.1 after titration with IR oxycodone dosed qid.,"Double-blind, randomized comparison of the analgesic and pharmacokinetic profiles of controlled- and immediate-release oral oxycodone in cancer pain patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11361046/),,6.0,228062,DB00497,Oxycodone
,16729270,volume of the first brain compartment,The volume of the first brain compartment was 35.4 mL with a half-life of equilibrium of 0.6 min.,Cerebral kinetics of oxycodone in conscious sheep. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16729270/),ml,35.4,231787,DB00497,Oxycodone
,16729270,half-life of equilibrium,The volume of the first brain compartment was 35.4 mL with a half-life of equilibrium of 0.6 min.,Cerebral kinetics of oxycodone in conscious sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16729270/),min,0.6,231788,DB00497,Oxycodone
,16729270,half-life,"The brain:blood equilibration of oxycodone was relatively slow (half-life of 7.2 min), with a large deep cerebral distribution volume (222.8 mL) for the second compartment and a moderate membrane permeability of 54.8 mL/min, which exceeded the nominal CBF (40 mL/min).",Cerebral kinetics of oxycodone in conscious sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16729270/),min,7.2,231789,DB00497,Oxycodone
,16729270,deep cerebral distribution volume,"The brain:blood equilibration of oxycodone was relatively slow (half-life of 7.2 min), with a large deep cerebral distribution volume (222.8 mL) for the second compartment and a moderate membrane permeability of 54.8 mL/min, which exceeded the nominal CBF (40 mL/min).",Cerebral kinetics of oxycodone in conscious sheep. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16729270/),ml,222.8,231790,DB00497,Oxycodone
,16729270,membrane permeability,"The brain:blood equilibration of oxycodone was relatively slow (half-life of 7.2 min), with a large deep cerebral distribution volume (222.8 mL) for the second compartment and a moderate membrane permeability of 54.8 mL/min, which exceeded the nominal CBF (40 mL/min).",Cerebral kinetics of oxycodone in conscious sheep. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16729270/),[ml] / [min],54.8,231791,DB00497,Oxycodone
,16729270,CBF,"The brain:blood equilibration of oxycodone was relatively slow (half-life of 7.2 min), with a large deep cerebral distribution volume (222.8 mL) for the second compartment and a moderate membrane permeability of 54.8 mL/min, which exceeded the nominal CBF (40 mL/min).",Cerebral kinetics of oxycodone in conscious sheep. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16729270/),[ml] / [min],40,231792,DB00497,Oxycodone
,16729270,Drug retention in,Drug retention in the brain was 1.3% after 45 min.,Cerebral kinetics of oxycodone in conscious sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16729270/),%,1.3,231793,DB00497,Oxycodone
,22417021,maximum venous concentration,"Maximum venous concentration and area under the concentration curve were approximately two-fold lower in the patient group for an equivalent dose, suggesting either reduced bioavailability or increased clearance: maximum venous concentration 0.14 ± 0.06 vs 0.05 ± 0.02 µg/ml (P <0.0001); area under the concentration curve 19.50 ± 9.15 vs 9.72 ± 2.71 µg/ml/minute (P <0.001) respectively.",Pharmacokinetics of oxycodone after subcutaneous administration in a critically ill population compared with a healthy cohort. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22417021/),[μg] / [ml],0.14,231938,DB00497,Oxycodone
,22417021,maximum venous concentration,"Maximum venous concentration and area under the concentration curve were approximately two-fold lower in the patient group for an equivalent dose, suggesting either reduced bioavailability or increased clearance: maximum venous concentration 0.14 ± 0.06 vs 0.05 ± 0.02 µg/ml (P <0.0001); area under the concentration curve 19.50 ± 9.15 vs 9.72 ± 2.71 µg/ml/minute (P <0.001) respectively.",Pharmacokinetics of oxycodone after subcutaneous administration in a critically ill population compared with a healthy cohort. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22417021/),[μg] / [ml],0.05,231939,DB00497,Oxycodone
,22417021,area under the concentration curve,"Maximum venous concentration and area under the concentration curve were approximately two-fold lower in the patient group for an equivalent dose, suggesting either reduced bioavailability or increased clearance: maximum venous concentration 0.14 ± 0.06 vs 0.05 ± 0.02 µg/ml (P <0.0001); area under the concentration curve 19.50 ± 9.15 vs 9.72 ± 2.71 µg/ml/minute (P <0.001) respectively.",Pharmacokinetics of oxycodone after subcutaneous administration in a critically ill population compared with a healthy cohort. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22417021/),[μg] / [min·ml],19.50,231940,DB00497,Oxycodone
,22417021,area under the concentration curve,"Maximum venous concentration and area under the concentration curve were approximately two-fold lower in the patient group for an equivalent dose, suggesting either reduced bioavailability or increased clearance: maximum venous concentration 0.14 ± 0.06 vs 0.05 ± 0.02 µg/ml (P <0.0001); area under the concentration curve 19.50 ± 9.15 vs 9.72 ± 2.71 µg/ml/minute (P <0.001) respectively.",Pharmacokinetics of oxycodone after subcutaneous administration in a critically ill population compared with a healthy cohort. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22417021/),[μg] / [min·ml],9.72,231941,DB00497,Oxycodone
,22417021,time to maximum venous concentration,"However, time to maximum venous concentration and mean residence time were not different, suggesting similar absorption rates: time to maximum venous concentration 22.10 ± 18.0 vs 20.50 ± 16.10 minutes (P=0.81); mean residence time 353 ± 191 vs 291 ± 80 minutes (P=0.26).",Pharmacokinetics of oxycodone after subcutaneous administration in a critically ill population compared with a healthy cohort. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22417021/),min,22.10,231942,DB00497,Oxycodone
,22417021,time to maximum venous concentration,"However, time to maximum venous concentration and mean residence time were not different, suggesting similar absorption rates: time to maximum venous concentration 22.10 ± 18.0 vs 20.50 ± 16.10 minutes (P=0.81); mean residence time 353 ± 191 vs 291 ± 80 minutes (P=0.26).",Pharmacokinetics of oxycodone after subcutaneous administration in a critically ill population compared with a healthy cohort. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22417021/),min,20.50,231943,DB00497,Oxycodone
,22417021,mean residence time,"However, time to maximum venous concentration and mean residence time were not different, suggesting similar absorption rates: time to maximum venous concentration 22.10 ± 18.0 vs 20.50 ± 16.10 minutes (P=0.81); mean residence time 353 ± 191 vs 291 ± 80 minutes (P=0.26).",Pharmacokinetics of oxycodone after subcutaneous administration in a critically ill population compared with a healthy cohort. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22417021/),min,353,231944,DB00497,Oxycodone
,22417021,mean residence time,"However, time to maximum venous concentration and mean residence time were not different, suggesting similar absorption rates: time to maximum venous concentration 22.10 ± 18.0 vs 20.50 ± 16.10 minutes (P=0.81); mean residence time 353 ± 191 vs 291 ± 80 minutes (P=0.26).",Pharmacokinetics of oxycodone after subcutaneous administration in a critically ill population compared with a healthy cohort. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22417021/),min,291,231945,DB00497,Oxycodone
>,18360598,bioavailability,The bioavailability of oxycodone is >60% and the bioavailability of morphine is 20%.,Oxycodone controlled release in cancer pain management. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18360598/),%,60,238891,DB00497,Oxycodone
,18360598,bioavailability,The bioavailability of oxycodone is >60% and the bioavailability of morphine is 20%.,Oxycodone controlled release in cancer pain management. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18360598/),%,20,238892,DB00497,Oxycodone
,18360598,half-life,"There is a rapid phase with a mean half-life of 37 min, accounting for 38% of the dose, and a slow phase with a half-life of 6.2 h, which accounts for the residual 62%.",Oxycodone controlled release in cancer pain management. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18360598/),min,37,238893,DB00497,Oxycodone
,18360598,half-life,"There is a rapid phase with a mean half-life of 37 min, accounting for 38% of the dose, and a slow phase with a half-life of 6.2 h, which accounts for the residual 62%.",Oxycodone controlled release in cancer pain management. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18360598/),h,6.2,238894,DB00497,Oxycodone
,16763013,CL(in),CL(in) across the BBB was estimated to 1910 microl/min x g brain.,In vivo blood-brain barrier transport of oxycodone in the rat: indications for active influx and implications for pharmacokinetics/pharmacodynamics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16763013/),[μl] / [g·min],1910,244789,DB00497,Oxycodone
,16763013,"K(p,uu)","K(p,uu) was estimated to 3.0, meaning that the unbound concentration of oxycodone in brain was 3 times higher than in blood, which is an indication of active influx of oxycodone at the BBB.",In vivo blood-brain barrier transport of oxycodone in the rat: indications for active influx and implications for pharmacokinetics/pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16763013/),,3.0,244790,DB00497,Oxycodone
,21491207,Plasma concentrations,"Plasma concentrations of oxycodone and noroxycodone ranged from 1.0 to 256.0 and 0.9-269.4 μg/L, respectively.",Is saliva a valid substitute for plasma in pharmacokinetic studies of oxycodone and its metabolites in patients with cancer? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21491207/),[μg] / [l],1.0 to 256.0,244815,DB00497,Oxycodone
,21491207,Plasma concentrations,"Plasma concentrations of oxycodone and noroxycodone ranged from 1.0 to 256.0 and 0.9-269.4 μg/L, respectively.",Is saliva a valid substitute for plasma in pharmacokinetic studies of oxycodone and its metabolites in patients with cancer? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21491207/),[μg] / [l],0.9-269.4,244816,DB00497,Oxycodone
,1958450,t1/2z,"Mean values of t1/2z, CL and Vss were 222 min, 0.78 l min-1 and 2.60 l kg-1, respectively.",The pharmacokinetics of oxycodone after intravenous injection in adults. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1958450/),min,222,251145,DB00497,Oxycodone
,1958450,CL,"Mean values of t1/2z, CL and Vss were 222 min, 0.78 l min-1 and 2.60 l kg-1, respectively.",The pharmacokinetics of oxycodone after intravenous injection in adults. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1958450/),[l] / [min],0.78,251146,DB00497,Oxycodone
,1958450,Vss,"Mean values of t1/2z, CL and Vss were 222 min, 0.78 l min-1 and 2.60 l kg-1, respectively.",The pharmacokinetics of oxycodone after intravenous injection in adults. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1958450/),[l] / [kg],2.60,251147,DB00497,Oxycodone
,1958450,"AUC(0,12) ratio","The mean AUC(0,12) ratio of noroxycodone to oxycodone was 0.33.",The pharmacokinetics of oxycodone after intravenous injection in adults. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1958450/),,0.33,251148,DB00497,Oxycodone
,18787997,peak APAP concentration,AC at 1 h resulted in a 25% reduction in peak APAP concentration from 48.6 to 36.3 mcg/mL (p = 0.012) with no significant difference when given at 2 or 3 h.,Effect of delayed activated charcoal on acetaminophen concentration after simulated overdose of oxycodone and acetaminophen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18787997/),[mcg] / [ml],48.6,256793,DB00497,Oxycodone
,18787997,peak APAP concentration,AC at 1 h resulted in a 25% reduction in peak APAP concentration from 48.6 to 36.3 mcg/mL (p = 0.012) with no significant difference when given at 2 or 3 h.,Effect of delayed activated charcoal on acetaminophen concentration after simulated overdose of oxycodone and acetaminophen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18787997/),[mcg] / [ml],36.3,256794,DB00497,Oxycodone
,24243216,Peak effects,Peak effects for pharmacodynamic measures were delayed with ORF (1-2 hours) versus OC and Oxy API (0.5-1 hour).,"Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24243216/),h,1-2,259209,DB00497,Oxycodone
,24243216,Peak effects,Peak effects for pharmacodynamic measures were delayed with ORF (1-2 hours) versus OC and Oxy API (0.5-1 hour).,"Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24243216/),h,0.5-1,259210,DB00497,Oxycodone
,34228875,absorption lag time,"However, the absorption lag time was 11.5 min in patients vs 14 min in healthy volunteers for controlled-release tablets (P < 0.001).",Effect of Roux-en-Y gastric bypass on the pharmacokinetic-pharmacodynamic relationships of liquid and controlled-release formulations of oxycodone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34228875/),min,11.5,259884,DB00497,Oxycodone
,34228875,absorption lag time,"However, the absorption lag time was 11.5 min in patients vs 14 min in healthy volunteers for controlled-release tablets (P < 0.001).",Effect of Roux-en-Y gastric bypass on the pharmacokinetic-pharmacodynamic relationships of liquid and controlled-release formulations of oxycodone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34228875/),min,14,259885,DB00497,Oxycodone
,34228875,oral bioavailability,"Furthermore, oral bioavailability was 14.4% higher in patients compared to healthy volunteers regardless of formulation type (P < 0.001).",Effect of Roux-en-Y gastric bypass on the pharmacokinetic-pharmacodynamic relationships of liquid and controlled-release formulations of oxycodone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34228875/),%,14.4,259886,DB00497,Oxycodone
,26364041,plasma oxycodone concentrations (MEC),"At the onset of pain, the plasma oxycodone concentrations (MEC) were similar in the two groups: median 60 ng/mL (range 37-73) in the 10 mg group and median 52 ng/mL (range 24-79) in the 50 mg group.",A Dose-Finding Study of Dexketoprofen in Patients Undergoing Laparoscopic Cholecystectomy: A Randomized Clinical Trial on Effects on the Analgesic Concentration of Oxycodone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26364041/),[ng] / [ml],60,260908,DB00497,Oxycodone
,26364041,plasma oxycodone concentrations (MEC),"At the onset of pain, the plasma oxycodone concentrations (MEC) were similar in the two groups: median 60 ng/mL (range 37-73) in the 10 mg group and median 52 ng/mL (range 24-79) in the 50 mg group.",A Dose-Finding Study of Dexketoprofen in Patients Undergoing Laparoscopic Cholecystectomy: A Randomized Clinical Trial on Effects on the Analgesic Concentration of Oxycodone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26364041/),[ng] / [ml],52,260909,DB00497,Oxycodone
,26364041,MEACs,"At the time of pain relief, the MEACs were 98 ng/mL (range 59-150) in the 10 mg group and 80 ng/mL (range 45-128) in the 50 mg group.",A Dose-Finding Study of Dexketoprofen in Patients Undergoing Laparoscopic Cholecystectomy: A Randomized Clinical Trial on Effects on the Analgesic Concentration of Oxycodone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26364041/),[ng] / [ml],98,260910,DB00497,Oxycodone
,26364041,MEACs,"At the time of pain relief, the MEACs were 98 ng/mL (range 59-150) in the 10 mg group and 80 ng/mL (range 45-128) in the 50 mg group.",A Dose-Finding Study of Dexketoprofen in Patients Undergoing Laparoscopic Cholecystectomy: A Randomized Clinical Trial on Effects on the Analgesic Concentration of Oxycodone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26364041/),[ng] / [ml],80,260911,DB00497,Oxycodone
,1485370,elimination half-lives,"There were no significant differences in the mean elimination half-lives between the intravenous (5.45 +/- 1.43 h), oral tablets (5.65 +/- 1.13 h), oral syrup (4.80 +/- 1.13 h), and rectal suppository (5.40 +/- 1.19 h) formulations of oxycodone.","Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1485370/),h,5.45,266219,DB00497,Oxycodone
,1485370,elimination half-lives,"There were no significant differences in the mean elimination half-lives between the intravenous (5.45 +/- 1.43 h), oral tablets (5.65 +/- 1.13 h), oral syrup (4.80 +/- 1.13 h), and rectal suppository (5.40 +/- 1.19 h) formulations of oxycodone.","Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1485370/),h,5.65,266220,DB00497,Oxycodone
,1485370,elimination half-lives,"There were no significant differences in the mean elimination half-lives between the intravenous (5.45 +/- 1.43 h), oral tablets (5.65 +/- 1.13 h), oral syrup (4.80 +/- 1.13 h), and rectal suppository (5.40 +/- 1.19 h) formulations of oxycodone.","Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1485370/),h,4.80,266221,DB00497,Oxycodone
,1485370,elimination half-lives,"There were no significant differences in the mean elimination half-lives between the intravenous (5.45 +/- 1.43 h), oral tablets (5.65 +/- 1.13 h), oral syrup (4.80 +/- 1.13 h), and rectal suppository (5.40 +/- 1.19 h) formulations of oxycodone.","Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1485370/),h,5.40,266222,DB00497,Oxycodone
,1485370,plasma clearance,"After intravenous administration, the mean plasma clearance of oxycodone was 25.5 +/- 10.1 L/h and the mean volume of distribution at steady state was 2.5 +/- 0.8 L/kg.","Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1485370/),[l] / [h],25.5,266223,DB00497,Oxycodone
,1485370,volume of distribution at steady state,"After intravenous administration, the mean plasma clearance of oxycodone was 25.5 +/- 10.1 L/h and the mean volume of distribution at steady state was 2.5 +/- 0.8 L/kg.","Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1485370/),[l] / [kg],2.5,266224,DB00497,Oxycodone
,1485370,normalized area under the curve (AUC/D),"The mean normalized area under the curve (AUC/D) obtained after intravenous dosing (48.2 +/- 30.2 micrograms.h/L/mg) was more than twice the AUC/D values obtained after the administration of oxycodone tablets (19.8 +/- 3.5 micrograms.h/L/mg), oxycodone syrup (17.5 +/- 5.3 micrograms.h/L/mg), and rectal suppository (20.3 +/- 5.1 micrograms.h/L/mg), indicating that the amount of oxycodone reaching the systemic circulation after the extravascular routes of administration was < 50% of that obtained after intravenous dosing.","Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1485370/),[h·μg] / [l·mg],48.2,266225,DB00497,Oxycodone
,1485370,AUC/D,"The mean normalized area under the curve (AUC/D) obtained after intravenous dosing (48.2 +/- 30.2 micrograms.h/L/mg) was more than twice the AUC/D values obtained after the administration of oxycodone tablets (19.8 +/- 3.5 micrograms.h/L/mg), oxycodone syrup (17.5 +/- 5.3 micrograms.h/L/mg), and rectal suppository (20.3 +/- 5.1 micrograms.h/L/mg), indicating that the amount of oxycodone reaching the systemic circulation after the extravascular routes of administration was < 50% of that obtained after intravenous dosing.","Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1485370/),[h·μg] / [l·mg],19.8,266226,DB00497,Oxycodone
,1485370,AUC/D,"The mean normalized area under the curve (AUC/D) obtained after intravenous dosing (48.2 +/- 30.2 micrograms.h/L/mg) was more than twice the AUC/D values obtained after the administration of oxycodone tablets (19.8 +/- 3.5 micrograms.h/L/mg), oxycodone syrup (17.5 +/- 5.3 micrograms.h/L/mg), and rectal suppository (20.3 +/- 5.1 micrograms.h/L/mg), indicating that the amount of oxycodone reaching the systemic circulation after the extravascular routes of administration was < 50% of that obtained after intravenous dosing.","Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1485370/),[h·μg] / [l·mg],17.5,266227,DB00497,Oxycodone
,1485370,AUC/D,"The mean normalized area under the curve (AUC/D) obtained after intravenous dosing (48.2 +/- 30.2 micrograms.h/L/mg) was more than twice the AUC/D values obtained after the administration of oxycodone tablets (19.8 +/- 3.5 micrograms.h/L/mg), oxycodone syrup (17.5 +/- 5.3 micrograms.h/L/mg), and rectal suppository (20.3 +/- 5.1 micrograms.h/L/mg), indicating that the amount of oxycodone reaching the systemic circulation after the extravascular routes of administration was < 50% of that obtained after intravenous dosing.","Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1485370/),[h·μg] / [l·mg],20.3,266228,DB00497,Oxycodone
,1485370,absorption lag times,"The mean absorption lag times after oxycodone tablets (0.52 +/- 0.33 h), oxycodone syrup (0.48 +/- 0.40 h), and rectal suppository (0.76 +/- 0.47 h) were consistent with the onset of pharmacological effects reported by the patients.","Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1485370/),h,0.52,266229,DB00497,Oxycodone
,1485370,absorption lag times,"The mean absorption lag times after oxycodone tablets (0.52 +/- 0.33 h), oxycodone syrup (0.48 +/- 0.40 h), and rectal suppository (0.76 +/- 0.47 h) were consistent with the onset of pharmacological effects reported by the patients.","Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1485370/),h,0.48,266230,DB00497,Oxycodone
,1485370,absorption lag times,"The mean absorption lag times after oxycodone tablets (0.52 +/- 0.33 h), oxycodone syrup (0.48 +/- 0.40 h), and rectal suppository (0.76 +/- 0.47 h) were consistent with the onset of pharmacological effects reported by the patients.","Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1485370/),h,0.76,266231,DB00497,Oxycodone
,26108255,Tmax,Median Tmax for crushed OxyContin® was the same as IR oxycodone and 3.25 hours shorter than intact OxyContin®.,Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26108255/),h,3.25,269263,DB00497,Oxycodone
,30189012,clearance,The haemodialysis clearance of oxycodone based on its recovery in dialysate was (mean ± SD) 8.4 ± 2.1 L/h.,Pharmacokinetics of oxycodone/naloxone and its metabolites in patients with end-stage renal disease during and between haemodialysis sessions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30189012/),[l] / [h],8.4,271360,DB00497,Oxycodone
,30189012,plasma elimination half-life,The geometric mean (coefficient of variation) plasma elimination half-life of oxycodone during the 4-h haemodialysis period was 3.9 h (39%) which was significantly shorter than the 5.7 h (22%) without haemodialysis.,Pharmacokinetics of oxycodone/naloxone and its metabolites in patients with end-stage renal disease during and between haemodialysis sessions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30189012/),h,3.9,271361,DB00497,Oxycodone
,30189012,plasma elimination half-life,The geometric mean (coefficient of variation) plasma elimination half-life of oxycodone during the 4-h haemodialysis period was 3.9 h (39%) which was significantly shorter than the 5.7 h (22%) without haemodialysis.,Pharmacokinetics of oxycodone/naloxone and its metabolites in patients with end-stage renal disease during and between haemodialysis sessions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30189012/),h,5.7,271362,DB00497,Oxycodone
